: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

COVID-19: Daily Top 10 Papers

Multiple Sclerosis

Free Subscription

Articles published in Mult Scler
Retrieve available abstracts of 501 articles:
HTML format

Single Articles

December 2021

LEEKOFF M, Culpepper W, Jin S, Lee-Wilk T, et al
Impact of comorbid post traumatic stress disorder on multiple sclerosis in military veterans: A population-based cohort study.
Mult Scler. 2021 Dec 2:13524585211058361. doi: 10.1177/13524585211058361.
PubMed Abstract available

November 2021

SARKAR P, Redondo J, Hares K, Bailey S, et al
Reduced expression of mitochondrial fumarate hydratase in progressive multiple sclerosis contributes to impaired in vitro mesenchymal stromal cell-mediated neuroprotection.
Mult Scler. 2021 Nov 29:13524585211060686. doi: 10.1177/13524585211060686.
PubMed Abstract available

OTERO-ROMERO S, Carbonell-Mirabent P, Midaglia L, Zuluaga M, et al
Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis.
Mult Scler. 2021 Nov 29:13524585211053001. doi: 10.1177/13524585211053001.
PubMed Abstract available

KIRA JI, Nakahara J, Sazonov DV, Kurosawa T, et al
Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study.
Mult Scler. 2021 Nov 17:13524585211055934. doi: 10.1177/13524585211055934.
PubMed Abstract available

SCHORR EM, Kurz D, Rossi KC, Zhang M, et al
Depression readmission risk is elevated in multiple sclerosis compared to other chronic illnesses.
Mult Scler. 2021 Nov 17:13524585211051316. doi: 10.1177/13524585211051316.
PubMed Abstract available

MARRIE RA, McKay K
Administrative data for observational research in multiple sclerosis: Opportunities and challenges.
Mult Scler. 2021 Nov 17:13524585211055787. doi: 10.1177/13524585211055787.
PubMed

MAUBEUGE N, Deloire MS, Brochet B, Charre-Morin J, et al
Validation of a Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) and comparison with reference batteries.
Mult Scler. 2021 Nov 12:13524585211054006. doi: 10.1177/13524585211054006.
PubMed Abstract available

MOUMDJIAN L, Moens B, Van Wijmeersh B, Leman M, et al
Application of step and beat alignment approaches and its effect on gait in progressive multiple sclerosis with severe cerebellar ataxia: A proof of concept case study.
Mult Scler. 2021 Nov 2:13524585211054000. doi: 10.1177/13524585211054000.
PubMed Abstract available

October 2021

MISICKA E, Davis MF, Kim W, Brugger SW, et al
A higher burden of multiple sclerosis genetic risk confers an earlier onset.
Mult Scler. 2021 Oct 28:13524585211053155. doi: 10.1177/13524585211053155.
PubMed Abstract available

PONCET-MEGEMONT L, Pereira B, Rollot F, Sormani MP, et al
Estimation of sample size in randomized controlled trials in multiple sclerosis studying annualized relapse rates: A systematic review.
Mult Scler. 2021 Oct 26:13524585211052400. doi: 10.1177/13524585211052400.
PubMed Abstract available

BERGAMASCHI R, Montomoli C
Air pollution is a risk factor for multiple sclerosis - Yes.
Mult Scler. 2021 Oct 22:13524585211035953. doi: 10.1177/13524585211035953.
PubMed

DELGADO-GARCIA G, Corona T
Air pollution is a risk factor for multiple sclerosis - No.
Mult Scler. 2021 Oct 22:13524585211026875. doi: 10.1177/13524585211026875.
PubMed

SAHRAIAN MA
Air pollution is a risk factor for multiple sclerosis - Commentary.
Mult Scler. 2021 Oct 22:13524585211046352. doi: 10.1177/13524585211046352.
PubMed

ZHONG M, van der Walt A, Stankovich J, Kalincik T, et al
Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
Mult Scler. 2021 Oct 8:13524585211049986. doi: 10.1177/13524585211049986.
PubMed Abstract available

UHER T, Havrdova EK, Benkert P, Bergsland N, et al
Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis.
Mult Scler. 2021 Oct 6:13524585211047977. doi: 10.1177/13524585211047977.
PubMed Abstract available

VILLOSLADA P
Personalized medicine for multiple sclerosis: How to integrate neurofilament light chain levels in the decision?
Mult Scler. 2021 Oct 6:13524585211049552. doi: 10.1177/13524585211049552.
PubMed

WEINSTOCK Z, Morrow S, Conway D, Fuchs T, et al
Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology.
Mult Scler. 2021 Oct 6:13524585211049397. doi: 10.1177/13524585211049397.
PubMed Abstract available

SOLOMON AJ, Kaisey M, Krieger SC, Chahin S, et al
Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States.
Mult Scler. 2021 Oct 6:13524585211048401. doi: 10.1177/13524585211048401.
PubMed Abstract available

BOSMA AR, Murley C, Aspling J, Hillert J, et al
Trajectories of sickness absence and disability pension days among people with multiple sclerosis by type of occupation.
Mult Scler. 2021 Oct 6:13524585211048759. doi: 10.1177/13524585211048759.
PubMed Abstract available

BAR-OR A, Wiendl H, Montalban X, Alvarez E, et al
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
Mult Scler. 2021 Oct 4:13524585211044479. doi: 10.1177/13524585211044479.
PubMed Abstract available

GROTHE M, Ellenberger D, von Podewils F, Stahmann A, et al
Epilepsy as a predictor of disease progression in multiple sclerosis.
Mult Scler. 2021 Oct 1:13524585211046739. doi: 10.1177/13524585211046739.
PubMed Abstract available

SANDROFF BM, Motl RW, Amato MP, Brichetto G, et al
Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study.
Mult Scler. 2021 Oct 1:13524585211048397. doi: 10.1177/13524585211048397.
PubMed Abstract available

BSTEH G, Durauer S, Assar H, Hegen H, et al
Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.
Mult Scler. 2021 Oct 1:13524585211049391. doi: 10.1177/13524585211049391.
PubMed Abstract available

GEORGIEVA ZG, Dffinger R, Kumararatne D, Coles AJ, et al
Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients.
Mult Scler. 2021 Oct 1:13524585211046786. doi: 10.1177/13524585211046786.
PubMed Abstract available

CAMERON MH, Hildebrand A, Hugos CL, Judd GI, et al
Free From Falls education and exercise program for reducing falls in people with multiple sclerosis: A randomized controlled trial.
Mult Scler. 2021 Oct 1:13524585211046898. doi: 10.1177/13524585211046898.
PubMed Abstract available

ROBERS MV, Chan C, Vajdi B, Chiong-Rivero H, et al
Hypertension and hypertension severity in Hispanics/Latinx with MS.
Mult Scler. 2021;27:1894-1901.
PubMed Abstract available

ELKJAER ML, Frisch T, Tonazzolli A, Rottger R, et al
Unbiased examination of genome-wide human endogenous retrovirus transcripts in MS brain lesions.
Mult Scler. 2021;27:1829-1837.
PubMed Abstract available

KOCH MW, Mostert JP, Uitdehaag B, Cutter G, et al
A comparison of clinical outcomes in PPMS in the INFORMS original trial data set.
Mult Scler. 2021;27:1864-1874.
PubMed Abstract available

KOCH MW, Metz L, Cutter G
An enrichment strategy for clinical trials in SPMS.
Mult Scler. 2021;27:1884-1893.
PubMed Abstract available

September 2021

BUSSAS M, Grahl S, Pongratz V, Berthele A, et al
Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers.
Mult Scler. 2021 Sep 30:13524585211044957. doi: 10.1177/13524585211044957.
PubMed Abstract available

KEVER A, Leavitt VM
Assessing diagnosis disclosure and concealment in multiple sclerosis: Development and initial validation of the DISCO-MS survey.
Mult Scler. 2021 Sep 9:13524585211037581. doi: 10.1177/13524585211037581.
PubMed Abstract available

KRYSKO KM, Anderson A, Singh J, McPolin K, et al
Risk factors for peripartum depression in women with multiple sclerosis.
Mult Scler. 2021 Sep 9:13524585211041108. doi: 10.1177/13524585211041108.
PubMed Abstract available

WOJCIK C, Jaworski M 3rd, Dwyer MG, Youngs M, et al
Benchmarks of meaningful improvement on neurocognitive tests in multiple sclerosis.
Mult Scler. 2021 Sep 9:13524585211044672. doi: 10.1177/13524585211044672.
PubMed Abstract available

TREMLETT H, Okuda DT, Lebrun-Frenay C
The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - No.
Mult Scler. 2021 Sep 8:13524585211035951. doi: 10.1177/13524585211035951.
PubMed

GNANAPAVAN S
The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - Yes.
Mult Scler. 2021 Sep 8:13524585211040223. doi: 10.1177/13524585211040223.
PubMed

MAKHANI N
The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - Commentary.
Mult Scler. 2021 Sep 8:13524585211044951. doi: 10.1177/13524585211044951.
PubMed

BRADLEY L
Delayed amantadine toxicity causing apparent progression of multiple sclerosis.
Mult Scler. 2021 Sep 5:13524585211035737. doi: 10.1177/13524585211035737.
PubMed Abstract available

ENZINGER C
Slowly expanding lesions are a marker of progressive multiple sclerosis - Commentary.
Mult Scler. 2021 Sep 3:13524585211040225. doi: 10.1177/13524585211040225.
PubMed

HARTUNG HP, Meuth SG, Thompson AJ
Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis.
Mult Scler. 2021;27:1473-1476.
PubMed

GOLD R, Arnold DL, Bar-Or A, Fox RJ, et al
Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
Mult Scler. 2021 Sep 1:13524585211037909. doi: 10.1177/13524585211037909.
PubMed Abstract available

August 2021

CONWAY DS, Marck CH
Comorbidities require special attention in minorities with multiple sclerosis.
Mult Scler. 2021 Aug 27:13524585211037578. doi: 10.1177/13524585211037578.
PubMed

BLASCHKE SJ, Ellenberger D, Flachenecker P, Hellwig K, et al
Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry.
Mult Scler. 2021 Aug 27:13524585211039753. doi: 10.1177/13524585211039753.
PubMed Abstract available

COHEN JA, Cameron MH, Goldman MD, Goodman AD, et al
A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
Mult Scler. 2021 Aug 27:13524585211035333. doi: 10.1177/13524585211035333.
PubMed Abstract available

GUERRA T, Bollo L, Trojano M, Iaffaldano P, et al
Dengue fever in a multiple sclerosis patient taking Ocrelizumab.
Mult Scler. 2021 Aug 27:13524585211030214. doi: 10.1177/13524585211030214.
PubMed Abstract available

ALONSO R, Galleguillos L
Dengue fever in a multiple sclerosis patient taking ocrelizumab: Clinical commentary.
Mult Scler. 2021 Aug 27:13524585211039750. doi: 10.1177/13524585211039750.
PubMed

ABBADESSA G, Lavorgna L, Treaba CA, Bonavita S, et al
Hemostatic factors in the pathogenesis of neuroinflammation in multiple sclerosis.
Mult Scler. 2021 Aug 19:13524585211039111. doi: 10.1177/13524585211039111.
PubMed Abstract available

BUTLER PAGNOTTI R, Hua LH, Miller JB
Cognition and disease characteristics in adult onset versus late onset multiple sclerosis.
Mult Scler. 2021 Aug 19:13524585211039112. doi: 10.1177/13524585211039112.
PubMed Abstract available

TILLAUT H, Degremont A, Kerbrat S, Roux J, et al
Pregnancy in women with multiple sclerosis in France from 2010 to 2015: Incidence, outcomes, and exposure to disease-modifying therapies.
Mult Scler. 2021 Aug 19:13524585211035376. doi: 10.1177/13524585211035376.
PubMed Abstract available

ROMMER PS, Bsteh G, Berger T, Zettl UK, et al
SARS-CoV-2 antibodies in multiple sclerosis patients depending on the vaccine mode of action?
Mult Scler. 2021 Aug 13:13524585211039128. doi: 10.1177/13524585211039128.
PubMed

MARCHESI O, Bonacchi R, Valsasina P, Preziosa P, et al
Functional and structural MRI correlates of executive functions in multiple sclerosis.
Mult Scler. 2021 Aug 13:13524585211033184. doi: 10.1177/13524585211033184.
PubMed Abstract available

CLAFLIN SB, Campbell JA, Mason DF, Kalincik T, et al
The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis.
Mult Scler. 2021 Aug 13:13524585211035948. doi: 10.1177/13524585211035948.
PubMed Abstract available

WEINSTOCK-GUTTMAN B, Bermel R, Cutter G, Freedman MS, et al
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial.
Mult Scler. 2021 Aug 12:13524585211035740. doi: 10.1177/13524585211035740.
PubMed Abstract available

DE MOL CL, Neuteboom RF, Jansen PR, White T, et al
White matter microstructural differences in children and genetic risk for multiple sclerosis: A population-based study.
Mult Scler. 2021 Aug 11:13524585211034826. doi: 10.1177/13524585211034826.
PubMed Abstract available

AYADI N, Oertel FC, Asseyer S, Rust R, et al
Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders.
Mult Scler. 2021 Aug 11:13524585211032801. doi: 10.1177/13524585211032801.
PubMed Abstract available

ZHENG F, Li Y, Zhuo Z, Duan Y, et al
Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder.
Mult Scler. 2021 Aug 11:13524585211032800. doi: 10.1177/13524585211032800.
PubMed Abstract available

COMI G, Dadon Y, Sasson N, Steinerman JR, et al
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.
Mult Scler. 2021 Aug 11:13524585211032803. doi: 10.1177/13524585211032803.
PubMed Abstract available

PANDIT L
Fair and equitable treatment for multiple sclerosis in resource-poor regions: The need for off-label therapies and regional treatment guidelines.
Mult Scler. 2021;27:1320-1322.
PubMed

July 2021

SORMANI MP, Schiavetti I, Landi D, Carmisciano L, et al
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study.
Mult Scler. 2021 Jul 30:13524585211035318. doi: 10.1177/13524585211035318.
PubMed Abstract available

ROTSTEIN D, Maxwell C, Tu K, Gatley J, et al
High prevalence of comorbidities at diagnosis in immigrants with multiple sclerosis.
Mult Scler. 2021 Jul 30:13524585211031791. doi: 10.1177/13524585211031791.
PubMed Abstract available

PITTERI M, Magliozzi R, Nicholas R, Ziccardi S, et al
Cerebrospinal fluid inflammatory profile of cognitive impairment in newly diagnosed multiple sclerosis patients.
Mult Scler. 2021 Jul 30:13524585211032510. doi: 10.1177/13524585211032510.
PubMed Abstract available

UHR L, Mateen FJ
COVID-19 vaccine hesitancy in multiple sclerosis: A cross-sectional survey.
Mult Scler. 2021 Jul 27:13524585211030647. doi: 10.1177/13524585211030647.
PubMed Abstract available

LAURSON-DOUBE J, Rijke N, Helme A, Baneke P, et al
Ethical use of off-label disease-modifying therapies for multiple sclerosis.
Mult Scler. 2021 Jul 26:13524585211030207. doi: 10.1177/13524585211030207.
PubMed Abstract available

KOCH MW, Mostert J, Repovic P, Bowen JD, et al
MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis.
Mult Scler. 2021 Jul 26:13524585211031801. doi: 10.1177/13524585211031801.
PubMed Abstract available

LONGINETTI E, Frisell T, Englund S, Reutfors J, et al
Risk of depression in multiple sclerosis across disease-modifying therapies.
Mult Scler. 2021 Jul 15:13524585211031128. doi: 10.1177/13524585211031128.
PubMed Abstract available

BOUMAN PM, Strijbis VI, Jonkman LE, Hulst HE, et al
Artificial double inversion recovery images for (juxta)cortical lesion visualization in multiple sclerosis.
Mult Scler. 2021 Jul 14:13524585211029860. doi: 10.1177/13524585211029860.
PubMed Abstract available

MONTALBAN X, Graves J, Midaglia L, Mulero P, et al
A smartphone sensor-based digital outcome assessment of multiple sclerosis.
Mult Scler. 2021 Jul 14:13524585211028561. doi: 10.1177/13524585211028561.
PubMed Abstract available

HOGESTOL EA, Ghezzo S, Nygaard GO, Espeseth T, et al
Functional connectivity in multiple sclerosis modelled as connectome stability: A 5-year follow-up study.
Mult Scler. 2021 Jul 14:13524585211030212. doi: 10.1177/13524585211030212.
PubMed Abstract available

WIJERATNE T, Carroll W
World Brain Day 2021: Global campaign to stop multiple sclerosis.
Mult Scler. 2021 Jul 14:13524585211030147. doi: 10.1177/13524585211030147.
PubMed

HARTUNG HP, Derfuss T, Cree BA, Sormani MP, et al
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
Mult Scler. 2021 Jul 9:13524585211024997. doi: 10.1177/13524585211024997.
PubMed Abstract available

VAN LIEROP ZY, Toorop AA, van Ballegoij WJ, Olde Dubbelink TB, et al
Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.
Mult Scler. 2021 Jul 9:13524585211028833. doi: 10.1177/13524585211028833.
PubMed Abstract available

SPELMAN T, Forsberg L, McKay K, Glaser A, et al
Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry.
Mult Scler. 2021 Jul 2:13524585211026272. doi: 10.1177/13524585211026272.
PubMed Abstract available

KALINOWSKA-LYSZCZARZ A, Tillema JM, Tobin WO, Guo Y, et al
Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis.
Mult Scler. 2021 Jul 2:13524585211024162. doi: 10.1177/13524585211024162.
PubMed Abstract available

NAUTA IM, Bertens D, van Dam M, Huiskamp M, et al
Performance validity in outpatients with multiple sclerosis and cognitive complaints.
Mult Scler. 2021 Jul 2:13524585211025780. doi: 10.1177/13524585211025780.
PubMed Abstract available

ESHAGHI A
Towards an objective classification of multiple sclerosis.
Mult Scler. 2021;27:1151-1152.
PubMed

CALDITO NG, O'Leary S, Stuve O
Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation.
Mult Scler. 2021;27:1306-1308.
PubMed Abstract available

MARRIE RA, Patel R, Bernstein CN, Bolton JM, et al
Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders.
Mult Scler. 2021;27:1284-1292.
PubMed Abstract available

CENCIONI MT, Ali R, Nicholas R, Muraro PA, et al
Defective CD19+CD24(hi)CD38(hi) transitional B-cell function in patients with relapsing-remitting MS.
Mult Scler. 2021;27:1187-1197.
PubMed Abstract available

June 2021

SCHONFELDER K, Schuh H, Pfister F, Kramer J, et al
Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
Mult Scler. 2021 Jun 24:13524585211022719. doi: 10.1177/13524585211022719.
PubMed Abstract available

MIZELL R, Chen H, Lambe J, Saidha S, et al
Association of retinal atrophy with cortical lesions and leptomeningeal enhancement in multiple sclerosis on 7T MRI.
Mult Scler. 2021 Jun 14:13524585211023343. doi: 10.1177/13524585211023343.
PubMed Abstract available

BOMMARITO G, Tarun A, Farouj Y, Preti MG, et al
Altered anterior default mode network dynamics in progressive multiple sclerosis.
Mult Scler. 2021 Jun 14:13524585211018116. doi: 10.1177/13524585211018116.
PubMed Abstract available

HIDALGO DE LA CRUZ M, Valsasina P, Meani A, Gallo A, et al
Differential association of cortical, subcortical and spinal cord damage with multiple sclerosis disability milestones: A multiparametric MRI study.
Mult Scler. 2021 Jun 14:13524585211020296. doi: 10.1177/13524585211020296.
PubMed Abstract available

WU J, Engdahl E, Gustafsson R, Fogdell-Hahn A, et al
High antibody levels against human herpesvirus-6A interact with lifestyle factors in multiple sclerosis development.
Mult Scler. 2021 Jun 14:13524585211022011. doi: 10.1177/13524585211022011.
PubMed Abstract available

VERCELLINO M, Marasciulo S, Grifoni S, Vallino-Costassa E, et al
Acute and chronic synaptic pathology in multiple sclerosis gray matter.
Mult Scler. 2021 Jun 14:13524585211022174. doi: 10.1177/13524585211022174.
PubMed Abstract available

CORTESE R, Battaglini M, Parodi F, Stromillo ML, et al
Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course.
Mult Scler. 2021 Jun 8:13524585211019650. doi: 10.1177/13524585211019650.
PubMed Abstract available

SADOVNICK AD, Yee IM, Criscuoli M, DeLuca GC, et al
Genes and environment in multiple sclerosis: Impact of temporal changes in the sex ratio on recurrence risks.
Mult Scler. 2021 Jun 8:13524585211020221. doi: 10.1177/13524585211020221.
PubMed Abstract available

KALINOWSKI A, Cutter G, Bozinov N, Hinman JA, et al
The timed 25-foot walk in a large cohort of multiple sclerosis patients.
Mult Scler. 2021 Jun 8:13524585211017013. doi: 10.1177/13524585211017013.
PubMed Abstract available

GARJANI A, Hunter R, Law GR, Middleton RM, et al
Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS Register.
Mult Scler. 2021 Jun 3:13524585211020435. doi: 10.1177/13524585211020435.
PubMed Abstract available

SCHMIERER K, Giovannoni G
MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Commentary.
Mult Scler. 2021;27:1006-1007.
PubMed

SCALFARI A
MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Yes.
Mult Scler. 2021;27:1002-1004.
PubMed

CROSS AH, Naismith RT
MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - No.
Mult Scler. 2021;27:1004-1005.
PubMed

ZACKOWSKI KM, Freeman J, Brichetto G, Centonze D, et al
Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance.
Mult Scler. 2021;27:989-1001.
PubMed Abstract available

MORROW SA, Conway D, Fuchs T, Wojcik C, et al
Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses.
Mult Scler. 2021;27:1077-1087.
PubMed Abstract available

NAYAK S, Sechi E, Flanagan EP, Messina S, et al
Inflammatory activity following motor progression due to critical CNS demyelinating lesions.
Mult Scler. 2021;27:1037-1045.
PubMed Abstract available

REDER AT
Thoracic flexion provokes circumferential dysesthesia: A symptom of thoracic cord lesions in MS.
Mult Scler. 2021;27:1008-1013.
PubMed Abstract available

May 2021

MESSINA S, Mariano R, Roca-Fernandez A, Cavey A, et al
Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis.
Mult Scler. 2021 May 28:13524585211018987. doi: 10.1177/13524585211018987.
PubMed Abstract available

SINGH M, Gavidia R, Dunietz GL, Washnock-Schmid E, et al
Validation of an obstructive sleep apnea symptom inventory in persons with multiple sclerosis.
Mult Scler. 2021 May 28:13524585211013014. doi: 10.1177/13524585211013014.
PubMed Abstract available

ROUX J, Kingwell E, Zhu F, Tremlett H, et al
Care consumption of people with multiple sclerosis: A multichannel sequence analysis in a population-based setting in British Columbia, Canada.
Mult Scler. 2021 May 28:13524585211016726. doi: 10.1177/13524585211016726.
PubMed Abstract available

MCMURRAN CE
Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - No.
Mult Scler. 2021 May 28:13524585211016722. doi: 10.1177/13524585211016722.
PubMed

CALVO-BARREIRO L, Clerico M, Espejo C
Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Yes.
Mult Scler. 2021 May 28:13524585211016723. doi: 10.1177/13524585211016723.
PubMed

HOHLFELD R
Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Commentary.
Mult Scler. 2021 May 28:13524585211018990. doi: 10.1177/13524585211018990.
PubMed

KEVER A, Buyukturkoglu K, Levin SN, Riley CS, et al
Associations of social network structure with cognition and amygdala volume in multiple sclerosis: An exploratory investigation.
Mult Scler. 2021 May 26:13524585211018349. doi: 10.1177/13524585211018349.
PubMed Abstract available

LAM KH, van Oirschot P, den Teuling B, Hulst HE, et al
Reliability, construct and concurrent validity of a smartphone-based cognition test in multiple sclerosis.
Mult Scler. 2021 May 26:13524585211018103. doi: 10.1177/13524585211018103.
PubMed Abstract available

DE STEFANO N, Sormani MP, Giovannoni G, Rammohan K, et al
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
Mult Scler. 2021 May 10:13524585211010294. doi: 10.1177/13524585211010294.
PubMed Abstract available

WOJCIK C, Fuchs TA, Tran H, Dwyer MG, et al
Staging and stratifying cognitive dysfunction in multiple sclerosis.
Mult Scler. 2021 May 6:13524585211011390. doi: 10.1177/13524585211011390.
PubMed Abstract available

BROWNLEE WJ, Solomon AJ
Misdiagnosis of multiple sclerosis: Time for action.
Mult Scler. 2021;27:805-806.
PubMed

LONGBRAKE EE, Mao-Draayer Y, Cascione M, Zielinski T, et al
Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.
Mult Scler. 2021;27:883-894.
PubMed Abstract available

CAI MT, Zheng Y, Shen CH, Yang F, et al
Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder.
Mult Scler. 2021;27:871-882.
PubMed Abstract available

KASSA RM, Sechi E, Flanagan EP, Kaufmann TJ, et al
Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions.
Mult Scler. 2021;27:895-902.
PubMed Abstract available

April 2021

HOLLEN C, Rice J, Park M, Yadav V, et al
Rituximab for treatment of refractory multiple sclerosis relapses during pregnancy.
Mult Scler. 2021 Apr 30:1352458521998937. doi: 10.1177/1352458521998937.
PubMed Abstract available

GUNGOR F, Tarakci E, Ozdemir-Acar Z, Soysal A, et al
The effects of supervised versus home Pilates-based core stability training on lower extremity muscle strength and postural sway in people with multiple sclerosis.
Mult Scler. 2021 Apr 28:13524585211012202. doi: 10.1177/13524585211012202.
PubMed Abstract available

VAN LIEROP ZY, Wieske L, Koel-Simmelink MJ, Chatterjee M, et al
Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.
Mult Scler. 2021 Apr 23:13524585211010097. doi: 10.1177/13524585211010097.
PubMed Abstract available

KHADADAH S, Kimoff RJ, Duquette P, Jobin V, et al
Effect of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea in multiple sclerosis: A randomized, double-blind, placebo-controlled trial (SAMS-PAP study).
Mult Scler. 2021 Apr 23:13524585211010390. doi: 10.1177/13524585211010390.
PubMed Abstract available

HARRISON AM, Safari R, Mercer T, Picariello F, et al
Which exercise and behavioural interventions show most promise for treating fatigue in multiple sclerosis? A network meta-analysis.
Mult Scler. 2021 Apr 20:1352458521996002. doi: 10.1177/1352458521996002.
PubMed Abstract available

ALLANACH JR, Farrell JW 3rd, Mesidor M, Karimi-Abdolrezaee S, et al
Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review.
Mult Scler. 2021 Apr 19:13524585211008760. doi: 10.1177/13524585211008760.
PubMed Abstract available

ZHOU Y, Cuellar-Partida G, Simpson Yap S, Lin X, et al
Utilising multi-large omics data to elucidate biological mechanisms within multiple sclerosis genetic susceptibly loci.
Mult Scler. 2021 Apr 19:13524585211004422. doi: 10.1177/13524585211004422.
PubMed Abstract available

PAPEIX C, Mazoyer J, Maillart E, Bensa C, et al
Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?
Mult Scler. 2021 Apr 19:13524585211006372. doi: 10.1177/13524585211006372.
PubMed Abstract available

CHATTERTON S, Withers B, Sutton IJ, Milliken ST, et al
Pregnancy post autologous stem cell transplant with BEAM conditioning for multiple sclerosis.
Mult Scler. 2021 Apr 19:13524585211005660. doi: 10.1177/13524585211005660.
PubMed Abstract available

CIOTTI JR, Eby NS, Brier MR, Wu GF, et al
Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica.
Mult Scler. 2021 Apr 19:13524585211007086. doi: 10.1177/13524585211007086.
PubMed Abstract available

FLEMING KM, Coote SB, Herring MP
Home-based Pilates for symptoms of anxiety, depression and fatigue among persons with multiple sclerosis: An 8-week randomized controlled trial.
Mult Scler. 2021 Apr 19:13524585211009216. doi: 10.1177/13524585211009216.
PubMed Abstract available

SCHOONHEIM MM, Pinter D, Prouskas SE, Broeders TA, et al
Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy.
Mult Scler. 2021 Apr 19:13524585211008743. doi: 10.1177/13524585211008743.
PubMed Abstract available

D'AMICO E, Zanghi A, Calogero AE, Patti F, et al
Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study.
Mult Scler. 2021 Apr 19:13524585211009208. doi: 10.1177/13524585211009208.
PubMed Abstract available

CORTESE M, Bjornevik K, Chitnis T, Ascherio A, et al
Aging with multiple sclerosis: A longitudinal study of physical function, mental health, and memory in two cohorts of US women.
Mult Scler. 2021 Apr 16:13524585211007739. doi: 10.1177/13524585211007739.
PubMed Abstract available

COOPER G, Chien C, Zimmermann H, Bellmann-Strobl J, et al
Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation.
Mult Scler. 2021 Apr 15:13524585211003479. doi: 10.1177/13524585211003479.
PubMed Abstract available

ACHIRON A, Dolev M, Menascu S, Zohar DN, et al
COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
Mult Scler. 2021 Apr 15:13524585211003476. doi: 10.1177/13524585211003476.
PubMed Abstract available

TROJANO M, Ramio-Torrenta L, Grimaldi LM, Lubetzki C, et al
A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.
Mult Scler. 2021 Apr 6:13524585211003020. doi: 10.1177/13524585211003020.
PubMed Abstract available

BESSING B, Honan CA, van der Mei I, Taylor BV, et al
Development and psychometric properties of the Multiple Sclerosis Knowledge Assessment Scale: Rasch analysis of a novel tool for evaluating MS knowledge.
Mult Scler. 2021;27:767-777.
PubMed Abstract available

VAN DAM M, Hulst HE, Schoonheim MM
Coupling structure and function in early MS: How a less diverse repertoire of brain function could lead to clinical progression.
Mult Scler. 2021;27:491-493.
PubMed

MANCINELLI CR, Scarpazza C, Cordioli C, De Rossi N, et al
Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
Mult Scler. 2021;27:790-794.
PubMed Abstract available

BIGAUT K, Fabacher T, Kremer L, Ongagna JC, et al
Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort.
Mult Scler. 2021;27:729-741.
PubMed Abstract available

KUNCHOK A, Lechner-Scott J, Granella F, Trojano M, et al
Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.
Mult Scler. 2021;27:695-705.
PubMed Abstract available

SECHI E, Messina S, Keegan BM, Buciuc M, et al
Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study.
Mult Scler. 2021;27:667-673.
PubMed Abstract available

DATTA P, Ciplea AI, Rewers-Felkins K, Baker T, et al
Cladribine transfer into human milk: A case report.
Mult Scler. 2021;27:799-801.
PubMed Abstract available

March 2021

HOWLETT-PRIETO Q, Feng X, Kramer JF, Kramer KJ, et al
Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis.
Mult Scler. 2021 Mar 30:13524585211003301. doi: 10.1177/13524585211003301.
PubMed Abstract available

THEODORSDOTTIR A, Debrabant B, Magyari M, Kant M, et al
Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry.
Mult Scler. 2021 Mar 29:13524585211003291. doi: 10.1177/13524585211003291.
PubMed Abstract available

CREE BA, Cohen JA, Reder AT, Tomic D, et al
Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.
Mult Scler. 2021 Mar 26:13524585211000280. doi: 10.1177/13524585211000280.
PubMed Abstract available

PORTACCIO E, Fonderico M, Hemmer B, Derfuss T, et al
Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
Mult Scler. 2021 Mar 25:13524585211005339. doi: 10.1177/13524585211005339.
PubMed Abstract available

LEE LE, Vavasour IM, Dvorak A, Liu H, et al
Cervical cord myelin abnormality is associated with clinical disability in multiple sclerosis.
Mult Scler. 2021 Mar 22:13524585211001780. doi: 10.1177/13524585211001780.
PubMed Abstract available

HARROUD A, Mitchell RE, Richardson TG, Morris JA, et al
Childhood obesity and multiple sclerosis: A Mendelian randomization study.
Mult Scler. 2021 Mar 22:13524585211001781. doi: 10.1177/13524585211001781.
PubMed Abstract available

BRIGGS FB, Krill D, Hill E, Conway DS, et al
Age of hypertension onset in multiple sclerosis patients.
Mult Scler. 2021 Mar 18:13524585211003016. doi: 10.1177/13524585211003016.
PubMed Abstract available

MASSAROTTI C, Sbragia E, Boffa G, Vercelli C, et al
Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis.
Mult Scler. 2021 Mar 12:13524585211000616. doi: 10.1177/13524585211000616.
PubMed Abstract available

SCHOONHEIM MM, Douw L, Broeders TA, Eijlers AJ, et al
The cerebellum and its network: Disrupted static and dynamic functional connectivity patterns and cognitive impairment in multiple sclerosis.
Mult Scler. 2021 Mar 8:1352458521999274. doi: 10.1177/1352458521999274.
PubMed Abstract available

MACHLANSKA A, Helbig G, Chromik K, Zapala M, et al
Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis.
Mult Scler. 2021 Mar 5:1352458521993070. doi: 10.1177/1352458521993070.
PubMed Abstract available

LORSCHEIDER J
When does a heap become a heap?
Mult Scler. 2021;27:329-330.
PubMed

BUTZKUEVEN H, Trojano M, Kappos L, Spelman T, et al
Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri((R)) Observational Program (TOP).
Mult Scler. 2021;27:410-419.
PubMed Abstract available

February 2021

SZILASIOVA J, Mikula P, Rosenberger J, Fedicova M, et al
Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss.
Mult Scler. 2021 Feb 26:1352458521998039. doi: 10.1177/1352458521998039.
PubMed Abstract available

FOX RJ, Raska P, Barro C, Karafa M, et al
Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
Mult Scler. 2021 Feb 26:1352458520986956. doi: 10.1177/1352458520986956.
PubMed Abstract available

COPETTI M, Liu D
Machine and deep learning in multiple sclerosis research are just powerful statistics - Commentary.
Mult Scler. 2021 Feb 24:1352458521996699. doi: 10.1177/1352458521996699.
PubMed

HARROUD A, Manousaki D, Butler-Laporte G, Mitchell RE, et al
The relative contributions of obesity, vitamin D, leptin, and adiponectin to multiple sclerosis risk: A Mendelian randomization mediation analysis.
Mult Scler. 2021 Feb 19:1352458521995484. doi: 10.1177/1352458521995484.
PubMed Abstract available

BINZER S, Jiang X, Hillert J, Manouchehrinia A, et al
Depression and multiple sclerosis: A bidirectional Mendelian randomisation study.
Mult Scler. 2021 Feb 19:1352458521996601. doi: 10.1177/1352458521996601.
PubMed Abstract available

LEMA DOPICO A, Choi S, Hua J, Li X, et al
Multi-layer analysis of quantitative 7 T magnetic resonance imaging in the cortex of multiple sclerosis patients reveals pathology associated with disability.
Mult Scler. 2021 Feb 18:1352458521994556. doi: 10.1177/1352458521994556.
PubMed Abstract available

HARROUD A, Marrie RA, Fitzgerald KC, Salter A, et al
Mendelian randomization provides no evidence for a causal role in the bidirectional relationship between depression and multiple sclerosis.
Mult Scler. 2021 Feb 16:1352458521993075. doi: 10.1177/1352458521993075.
PubMed Abstract available

BESSING B, Hussain MA, Claflin SB, Chen J, et al
Changes in multiple sclerosis symptoms are associated with changes in work productivity of people living with multiple sclerosis.
Mult Scler. 2021 Feb 16:1352458521994557. doi: 10.1177/1352458521994557.
PubMed Abstract available

BELVISI D, Canevelli M, Baione V, Buscarinu MC, et al
Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation.
Mult Scler. 2021 Feb 10:1352458520987541. doi: 10.1177/1352458520987541.
PubMed Abstract available

MIDAGLIA L, Sastre-Garriga J, Pappolla A, Quibus L, et al
The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia.
Mult Scler. 2021 Feb 10:1352458520988148. doi: 10.1177/1352458520988148.
PubMed Abstract available

VELDKAMP R, Kalron A, Baert I, Hamalainen P, et al
Differential effects and discriminative validity of motor and cognitive tasks varying in difficulty on cognitive-motor interference in persons with multiple sclerosis.
Mult Scler. 2021 Feb 10:1352458520986960. doi: 10.1177/1352458520986960.
PubMed Abstract available

KRASNIUK S, Classen S, Morrow SA, Alvarez L, et al
Clinical predictors of driving simulator performance in drivers with multiple sclerosis.
Mult Scler. 2021 Feb 10:1352458521992507. doi: 10.1177/1352458521992507.
PubMed Abstract available

DAS J, Snowden JA, Burman J, Freedman MS, et al
Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.
Mult Scler. 2021 Feb 10:1352458520985238. doi: 10.1177/1352458520985238.
PubMed Abstract available

Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis.
Mult Scler. 2021 Feb 2:1352458520978354. doi: 10.1177/1352458520978354.
PubMed Abstract available

NYIRENDA MH, Fadda G, Healy LM, Mexhitaj I, et al
Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis.
Mult Scler. 2021 Feb 1:1352458521989090. doi: 10.1177/1352458521989090.
PubMed Abstract available

YEH EA
Real-world outcomes in pediatric MS: Psychiatric comorbidities and school performance.
Mult Scler. 2021;27:165-166.
PubMed

SALTER A, Stahmann A, Ellenberger D, Fneish F, et al
Data harmonization for collaborative research among MS registries: A case study in employment.
Mult Scler. 2021;27:281-289.
PubMed Abstract available

January 2021

MANOUCHEHRINIA A, Kingwell E, Zhu F, Tremlett H, et al
A multiple sclerosis disease progression measure based on cumulative disability.
Mult Scler. 2021 Jan 25:1352458520988632. doi: 10.1177/1352458520988632.
PubMed Abstract available

JALUSIC KO, Ellenberger D, Rommer P, Stahmann A, et al
Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care.
Mult Scler. 2021 Jan 20:1352458520985118. doi: 10.1177/1352458520985118.
PubMed Abstract available

BLACK LJ, Hetherton S, Forkan M, Gonzales EG, et al
An exploratory study of diet in childhood and young adulthood and adult-onset multiple sclerosis.
Mult Scler. 2021 Jan 19:1352458520986964. doi: 10.1177/1352458520986964.
PubMed Abstract available

ROOS I, Leray E, Frascoli F, Casey R, et al
Determinants of therapeutic lag in multiple sclerosis.
Mult Scler. 2021 Jan 11:1352458520981300. doi: 10.1177/1352458520981300.
PubMed Abstract available

FITZGERALD KC, Damian A, Conway D, Mowry EM, et al
Vascular comorbidity is associated with lower brain volumes and lower neuroperformance in a large multiple sclerosis cohort.
Mult Scler. 2021 Jan 8:1352458520984746. doi: 10.1177/1352458520984746.
PubMed Abstract available

GONZALEZ-ESCAMILLA G, Groppa S
7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centres - No.
Mult Scler. 2021 Jan 6:1352458520969662. doi: 10.1177/1352458520969662.
PubMed

SATI P, Reich DS
7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centers - Commentary.
Mult Scler. 2021 Jan 6:1352458520981738. doi: 10.1177/1352458520981738.
PubMed

LOUAPRE C, Beigneux Y
7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centres - Yes.
Mult Scler. 2021 Jan 6:1352458520972270. doi: 10.1177/1352458520972270.
PubMed

ROLLOT F, Casey R, Leray E, Debouverie M, et al
Cumulative effects of therapies on disability in relapsing multiple sclerosis.
Mult Scler. 2021 Jan 6:1352458520980366. doi: 10.1177/1352458520980366.
PubMed Abstract available

MARRIE RA, Leung S, Cutter GR, Fox RJ, et al
Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis.
Mult Scler. 2021 Jan 5:1352458520981370. doi: 10.1177/1352458520981370.
PubMed Abstract available

AMATO MP, Portaccio E, De Meo E
Understanding the pathophysiology of cognitive changes in MS: A step forward.
Mult Scler. 2021;27:4-5.
PubMed

BISTROM M, Hultdin J, Sundstrom P
Response to 'Mendelian randomization analysis does not support a role for leptin in multiple sclerosis'.
Mult Scler. 2021;27:161-162.
PubMed

AL-ARAJI S, Ciccarelli O
A possible case of serum sickness after ocrelizumab infusion - Commentary.
Mult Scler. 2021;27:158-159.
PubMed Abstract available

LIBERTINOVA J, Meluzinova E, Nema E, Rockova P, et al
Elevated D-dimer as an immediate response to alemtuzumab treatment.
Mult Scler. 2021;27:151-154.
PubMed Abstract available

ZHANG J, Giorgio A, Vinciguerra C, Stromillo ML, et al
Gray matter atrophy cannot be fully explained by white matter damage in patients with MS.
Mult Scler. 2021;27:39-51.
PubMed Abstract available

GEORGE IC, El Mendili MM, Inglese M, Azevedo CJ, et al
Cerebellar volume loss in radiologically isolated syndrome.
Mult Scler. 2021;27:130-133.
PubMed Abstract available

December 2020

NIELSEN NM, Gortz S, Hjalgrim H, Rostgaard K, et al
Maternal diabetes and risk of multiple sclerosis in the offspring: A Danish nationwide register-based cohort study.
Mult Scler. 2020 Dec 17:1352458520977120. doi: 10.1177/1352458520977120.
PubMed Abstract available

GALLO A, Bisecco A
Psychological resilience explains functional variability across people with multiple sclerosis - Commentary.
Mult Scler. 2020 Dec 17:1352458520978213. doi: 10.1177/1352458520978213.
PubMed

LEAVITT VM, Kever A
Psychological resilience explains functional variability across people with multiple sclerosis - Yes.
Mult Scler. 2020 Dec 17:1352458520972263. doi: 10.1177/1352458520972263.
PubMed

PLOUGHMAN M
Psychological resilience explains functional variability across people with multiple sclerosis - No.
Mult Scler. 2020 Dec 17:1352458520973633. doi: 10.1177/1352458520973633.
PubMed

COMABELLA M, Deutschmann C, Midaglia L, Schierack P, et al
Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis.
Mult Scler. 2020 Dec 17:1352458520980141. doi: 10.1177/1352458520980141.
PubMed Abstract available

HYLAND MH, Robb JF
Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - Yes.
Mult Scler. 2020 Dec 16:1352458520973640. doi: 10.1177/1352458520973640.
PubMed

MOCCIA M
Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - No.
Mult Scler. 2020 Dec 16:1352458520968815. doi: 10.1177/1352458520968815.
PubMed

D'HAESELEER M
Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - Commentary.
Mult Scler. 2020 Dec 16:1352458520979303. doi: 10.1177/1352458520979303.
PubMed

CALABRESI PA, Arnold DL, Sangurdekar D, Singh CM, et al
Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.
Mult Scler. 2020 Dec 14:1352458520972573. doi: 10.1177/1352458520972573.
PubMed Abstract available

FILIPPATOU AG, Moniruzzaman M, Sotirchos ES, Fitzgerald KC, et al
Serum ceramide levels are altered in multiple sclerosis.
Mult Scler. 2020 Dec 14:1352458520971816. doi: 10.1177/1352458520971816.
PubMed Abstract available

CHAN CK, Tian F, Pimentel Maldonado D, Mowry EM, et al
Depression in multiple sclerosis across the adult lifespan.
Mult Scler. 2020 Dec 14:1352458520979304. doi: 10.1177/1352458520979304.
PubMed Abstract available

TAPIA-MALTOS MA, Trevino-Frenk I, Garcia-Gonzalez HB, Rosetti M, et al
Identification of regulatory T cell molecules associated with severity of multiple sclerosis.
Mult Scler. 2020 Dec 10:1352458520977045. doi: 10.1177/1352458520977045.
PubMed Abstract available

NAUTA IM, Kulik SD, Breedt LC, Eijlers AJ, et al
Functional brain network organization measured with magnetoencephalography predicts cognitive decline in multiple sclerosis.
Mult Scler. 2020 Dec 9:1352458520977160. doi: 10.1177/1352458520977160.
PubMed Abstract available

JACOBS BM, Smets I, Giovannoni G, Noyce A, et al
Regarding: Nicotinic acetylcholine receptors alpha7 and alpha9 modify tobacco smoke risk for multiple sclerosis.
Mult Scler. 2020 Dec 8:1352458520969941. doi: 10.1177/1352458520969941.
PubMed

BRIGGS F
Response to Jacobs et al, Nicotinic acetylcholine receptors alpha7 and alpha9 modify tobacco smoke risk for multiple sclerosis.
Mult Scler. 2020 Dec 8:1352458520977027. doi: 10.1177/1352458520977027.
PubMed

KOUBIYR I, Deloire M, Brochet B, Besson P, et al
Structural constraints of functional connectivity drive cognitive impairment in the early stages of multiple sclerosis.
Mult Scler. 2020 Dec 7:1352458520971807. doi: 10.1177/1352458520971807.
PubMed Abstract available

VUKUSIC S, Ionescu I, Cornu C, Bossard N, et al
Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study.
Mult Scler. 2020 Dec 3:1352458520978218. doi: 10.1177/1352458520978218.
PubMed Abstract available

RAMANUJAM R, Zhu F, Fink K, Karrenbauer VD, et al
Accurate classification of secondary progression in multiple sclerosis using a decision tree.
Mult Scler. 2020 Dec 2:1352458520975323. doi: 10.1177/1352458520975323.
PubMed Abstract available

SHAH S
Real-world evidence: One tweet at a time.
Mult Scler. 2020;26:1965-1966.
PubMed

COETZEE T, Thompson AJ
Atlas of MS 2020: Informing global policy change.
Mult Scler. 2020;26:1807-1808.
PubMed

PILUTTI LA, Fakolade A
Rehabilitation should be prescribed acutely in motor relapses - Commentary.
Mult Scler. 2020;26:1825-1827.
PubMed

November 2020

STEPHENS S, Berenbaum T, Finlayson M, Motl RW, et al
Youth with multiple sclerosis have low levels of fitness.
Mult Scler. 2020 Nov 27:1352458520974360. doi: 10.1177/1352458520974360.
PubMed Abstract available

ROMEO AR, Rowles WM, Schleimer ES, Barba P, et al
An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis.
Mult Scler. 2020 Nov 25:1352458520968814. doi: 10.1177/1352458520968814.
PubMed Abstract available

LANGESKOV-CHRISTENSEN M, Hvid LG, Jensen HB, Nielsen HH, et al
Efficacy of high-intensity aerobic exercise on cognitive performance in people with multiple sclerosis: A randomized controlled trial.
Mult Scler. 2020 Nov 24:1352458520973619. doi: 10.1177/1352458520973619.
PubMed Abstract available

KLISTORNER S, Barnett MH, Yiannikas C, Barton J, et al
Expansion of chronic lesions is linked to disease progression in relapsing-remitting multiple sclerosis patients.
Mult Scler. 2020 Nov 20:1352458520974357. doi: 10.1177/1352458520974357.
PubMed Abstract available

IAFFALDANO P, Lucisano G, Patti F, Brescia Morra V, et al
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.
Mult Scler. 2020 Nov 19:1352458520974366. doi: 10.1177/1352458520974366.
PubMed Abstract available

LARONI A, Schiavetti I, Sormani MP, Uccelli A, et al
COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments.
Mult Scler. 2020 Nov 18:1352458520971817. doi: 10.1177/1352458520971817.
PubMed Abstract available

CREE BA, Magnusson B, Rouyrre N, Fox RJ, et al
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
Mult Scler. 2020 Nov 18:1352458520971819. doi: 10.1177/1352458520971819.
PubMed Abstract available

GLUKHOVSKY L, Kurz D, Brandstadter R, Leavitt VM, et al
Depression and cognitive function in early multiple sclerosis: Multitasking is more sensitive than traditional assessments.
Mult Scler. 2020 Nov 16:1352458520958359. doi: 10.1177/1352458520958359.
PubMed Abstract available

PREZIOSA P, Pagani E, Moiola L, Rodegher M, et al
Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis.
Mult Scler. 2020 Nov 13:1352458520969105. doi: 10.1177/1352458520969105.
PubMed Abstract available

HEITMANN H, Andlauer TFM, Korn T, Muhlau M, et al
Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms.
Mult Scler. 2020 Nov 12:1352458520972279. doi: 10.1177/1352458520972279.
PubMed Abstract available

SACCO R, Braga A, Disanto G, Digesu GA, et al
Effectiveness of percutaneous posterior tibial nerve stimulation for the management of bowel dysfunction in multiple sclerosis patients.
Mult Scler. 2020 Nov 12:1352458520972267. doi: 10.1177/1352458520972267.
PubMed Abstract available

KARIM ME, Pellegrini F, Platt RW, Simoneau G, et al
The use and quality of reporting of propensity score methods in multiple sclerosis literature: A review.
Mult Scler. 2020 Nov 12:1352458520972557. doi: 10.1177/1352458520972557.
PubMed Abstract available

AVILA M, Okai A, Thakolwiboon S, O'Bryan C, et al
The effect of tonsillectomy on John Cunningham virus serological status in multiple sclerosis patients: A retrospective case-control study.
Mult Scler. 2020 Nov 12:1352458520971822. doi: 10.1177/1352458520971822.
PubMed Abstract available

WALTON C, King R, Rechtman L, Kaye W, et al
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.
Mult Scler. 2020 Nov 11:1352458520970841. doi: 10.1177/1352458520970841.
PubMed Abstract available

HEDSTROM AK, Olsson T, Alfredsson L
Cotinine as a measure of smoking in observational studies of multiple sclerosis.
Mult Scler. 2020 Nov 10:1352458520968803. doi: 10.1177/1352458520968803.
PubMed Abstract available

LAM KH, Meijer KA, Loonstra FC, Coerver E, et al
Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis.
Mult Scler. 2020 Nov 5:1352458520968797. doi: 10.1177/1352458520968797.
PubMed Abstract available

BUYUKTURKOGLU K, Zeng D, Bharadwaj S, Tozlu C, et al
Classifying multiple sclerosis patients on the basis of SDMT performance using machine learning.
Mult Scler. 2020 Nov 4:1352458520958362. doi: 10.1177/1352458520958362.
PubMed Abstract available

October 2020

LOZINSKI BM, Yong VW
Exercise and the brain in multiple sclerosis.
Mult Scler. 2020 Oct 30:1352458520969099. doi: 10.1177/1352458520969099.
PubMed Abstract available

AFZAL HMR, Luo S, Ramadan S, Lechner-Scott J, et al
The emerging role of artificial intelligence in multiple sclerosis imaging.
Mult Scler. 2020 Oct 28:1352458520966298. doi: 10.1177/1352458520966298.
PubMed Abstract available

PROSPERINI L, Haggiag S, Tortorella C, Galgani S, et al
Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression.
Mult Scler. 2020 Oct 26:1352458520964778. doi: 10.1177/1352458520964778.
PubMed Abstract available

STRIK M, Chard DT, Dekker I, Meijer KA, et al
Increased functional sensorimotor network efficiency relates to disability in multiple sclerosis.
Mult Scler. 2020 Oct 26:1352458520966292. doi: 10.1177/1352458520966292.
PubMed Abstract available

KOSCH R, Schiffmann I, Daumer M, Lederer C, et al
Long-term prognostic counselling in people with multiple sclerosis using an online analytical processing tool.
Mult Scler. 2020 Oct 26:1352458520964774. doi: 10.1177/1352458520964774.
PubMed Abstract available

TECCHIO F, Bertoli M, Gianni E, L'Abbate T, et al
Parietal dysfunctional connectivity in depression in multiple sclerosis.
Mult Scler. 2020 Oct 21:1352458520964412. doi: 10.1177/1352458520964412.
PubMed

JAEGER S, Paul F, Finke C
Functional connectivity alterations of striato-cortical circuits in multiple sclerosis.
Mult Scler. 2020 Oct 21:1352458520966303. doi: 10.1177/1352458520966303.
PubMed

BERMEL RA, Fedler JK, Kaiser P, Novalis C, et al
Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis.
Mult Scler. 2020 Oct 15:1352458520964409. doi: 10.1177/1352458520964409.
PubMed Abstract available

MARRIE RA, Walld R, Bolton JM, Sareen J, et al
Effect of mood and anxiety disorders on health care utilization in multiple sclerosis.
Mult Scler. 2020 Oct 13:1352458520963880. doi: 10.1177/1352458520963880.
PubMed Abstract available

CASTELLI L, Quartuccio ME, Ruggieri S, De Giglio L, et al
'Posture second' strategy predicts disability progression in multiple sclerosis.
Mult Scler. 2020 Oct 13:1352458520963926. doi: 10.1177/1352458520963926.
PubMed Abstract available

VEREB D, Toth E, Bozsik B, Kiraly A, et al
Altered brain network function during attention-modulated visual processing in multiple sclerosis.
Mult Scler. 2020 Oct 5:1352458520958360. doi: 10.1177/1352458520958360.
PubMed Abstract available

LANGER-GOULD A, Black LJ, Waubant E, Smith JB, et al
Seafood, fatty acid biosynthesis genes, and multiple sclerosis susceptibility.
Mult Scler. 2020;26:1476-1485.
PubMed Abstract available

CHEN J, Taylor B, Winzenberg T, Palmer AJ, et al
Comorbidities are prevalent and detrimental for employment outcomes in people of working age with multiple sclerosis.
Mult Scler. 2020;26:1550-1559.
PubMed Abstract available

HULST HE, Penner IK
Cognition and its relation to brain health in patients with MS.
Mult Scler. 2020;26:1611-1613.
PubMed

HOBART J, Giovannoni G
Cognition and its relation to brain health in patients with MS: Response to letter.
Mult Scler. 2020;26:1613-1614.
PubMed

AZEVEDO CJ, Zamvil SS
New cases of vasculitis after alemtuzumab.
Mult Scler. 2020;26:1606-1608.
PubMed

September 2020

PISA M, Chieffo R, Congiu M, Dalla Costa G, et al
Intracortical motor conduction is associated with hand dexterity in progressive multiple sclerosis.
Mult Scler. 2020 Sep 25:1352458520960374. doi: 10.1177/1352458520960374.
PubMed Abstract available

FERRE L, Mogavero A, Clarelli F, Moiola L, et al
Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis.
Mult Scler. 2020 Sep 25:1352458520961690. doi: 10.1177/1352458520961690.
PubMed Abstract available

BOESEN MS, Blinkenberg M, Thygesen LC, Eriksson F, et al
School performance, psychiatric comorbidity, and healthcare utilization in pediatric multiple sclerosis: A nationwide population-based observational study.
Mult Scler. 2020 Sep 25:1352458520959673. doi: 10.1177/1352458520959673.
PubMed Abstract available

CALVI A, Haider L, Prados F, Tur C, et al
In vivo imaging of chronic active lesions in multiple sclerosis.
Mult Scler. 2020 Sep 23:1352458520958589. doi: 10.1177/1352458520958589.
PubMed Abstract available

RIVA A, Barcella V, Benatti SV, Capobianco M, et al
Vaccinations in patients with multiple sclerosis: A Delphi consensus statement.
Mult Scler. 2020 Sep 17:1352458520952310. doi: 10.1177/1352458520952310.
PubMed Abstract available

MOIOLA L, Barcella V, Benatti S, Capobianco M, et al
The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement.
Mult Scler. 2020 Sep 17:1352458520952311. doi: 10.1177/1352458520952311.
PubMed Abstract available

FEYS P, Swinnen E
Powered exoskeletons for walking in multiple sclerosis.
Mult Scler. 2020 Sep 15:1352458520958351. doi: 10.1177/1352458520958351.
PubMed

WEE SK, Ho CY, Tan SL, Ong CH, et al
Enhancing quality of life in progressive multiple sclerosis with powered robotic exoskeleton.
Mult Scler. 2020 Sep 15:1352458520943080. doi: 10.1177/1352458520943080.
PubMed Abstract available

CORDANI C, Hidalgo de la Cruz M, Meani A, Valsasina P, et al
MRI correlates of clinical disability and hand-motor performance in multiple sclerosis phenotypes.
Mult Scler. 2020 Sep 14:1352458520958356. doi: 10.1177/1352458520958356.
PubMed Abstract available

ZHANG Y, Taylor BV, Simpson S Jr, Blizzard L, et al
Feelings of depression, pain and walking difficulties have the largest impact on the quality of life of people with multiple sclerosis, irrespective of clinical phenotype.
Mult Scler. 2020 Sep 14:1352458520958369. doi: 10.1177/1352458520958369.
PubMed Abstract available

BRIGGS FB
Nicotinic acetylcholine receptors alpha7 and alpha9 modifies tobacco smoke risk for multiple sclerosis.
Mult Scler. 2020 Sep 14:1352458520958361. doi: 10.1177/1352458520958361.
PubMed Abstract available

MARTINO M, Magioncalda P, El Mendili MM, Droby A, et al
Depression is associated with disconnection of neurotransmitter-related nuclei in multiple sclerosis.
Mult Scler. 2020 Sep 10:1352458520948214. doi: 10.1177/1352458520948214.
PubMed Abstract available

CHEN J, Taylor B, Blizzard L, Simpson-Yap S, et al
Risk factors for leaving employment due to multiple sclerosis and changes in risk over the past decades: Using competing risk survival analysis.
Mult Scler. 2020 Sep 3:1352458520954167. doi: 10.1177/1352458520954167.
PubMed Abstract available

YILMAZER C, Lamers I, Solaro C, Feys P, et al
Clinical perspective on pain in multiple sclerosis.
Mult Scler. 2020 Sep 3:1352458520952015. doi: 10.1177/1352458520952015.
PubMed Abstract available

HAWTON A, Goodwin E, Boddy K, Freeman J, et al
Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years.
Mult Scler. 2020 Sep 3:1352458520954172. doi: 10.1177/1352458520954172.
PubMed Abstract available

JOISTEN N, Proschinger S, Rademacher A, Schenk A, et al
High-intensity interval training reduces neutrophil-to-lymphocyte ratio in persons with multiple sclerosis during inpatient rehabilitation.
Mult Scler. 2020 Sep 3:1352458520951382. doi: 10.1177/1352458520951382.
PubMed Abstract available

CICCARELLI O, Cohen JA, Thompson A
Response of the multiple sclerosis community to COVID-19.
Mult Scler. 2020;26:1134-1136.
PubMed

YAM C, Jokubaitis V, Hellwig K, Dobson R, et al
MS, pregnancy and COVID-19.
Mult Scler. 2020;26:1137-1146.
PubMed Abstract available

MECA-LALLANA V
COVID-19 will change MS care forever - Yes.
Mult Scler. 2020;26:1147-1148.
PubMed

PREZIOSA P, Rocca MA, Filippi M
COVID-19 will change MS care forever - No.
Mult Scler. 2020;26:1149-1151.
PubMed

August 2020

MIDAGLIA L, Otero S, Baro F, Montalban X, et al
Menopause and multiple sclerosis: Influence on prognosis and role of disease-modifying drugs and hormonal replacement therapy.
Mult Scler. 2020 Aug 28:1352458520952022. doi: 10.1177/1352458520952022.
PubMed Abstract available

DISANTO G, Ripellino P, Riccitelli GC, Sacco R, et al
De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis.
Mult Scler. 2020 Aug 25:1352458520952036. doi: 10.1177/1352458520952036.
PubMed Abstract available

BOFFA G, Sbragia E, Raiola AM, Varaldo R, et al
Autologous hematopoietic stem cell transplantation following alemtuzumab therapy in aggressive multiple sclerosis: A report of three cases.
Mult Scler. 2020 Aug 25:1352458520914818. doi: 10.1177/1352458520914818.
PubMed Abstract available

SMITH AD, Prokopiusova T, Jones R, Burge T, et al
Functional electrical stimulation for foot drop in people with multiple sclerosis: The relevance and importance of addressing quality of movement.
Mult Scler. 2020 Aug 24:1352458520923958. doi: 10.1177/1352458520923958.
PubMed Abstract available

SADIGH G, Lava N, Switchenko J, Duszak R Jr, et al
Patient-reported financial toxicity in multiple sclerosis: Predictors and association with care non-adherence.
Mult Scler. 2020 Aug 18:1352458520913977. doi: 10.1177/1352458520913977.
PubMed Abstract available

JORDAN AL, Yang J, Fisher CJ, Racke MK, et al
Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.
Mult Scler. 2020 Aug 18:1352458520949158. doi: 10.1177/1352458520949158.
PubMed Abstract available

SEYMAN E, Jones A, Guenette M, Vosoughi R, et al
Clinical and MRI characteristics of multiple sclerosis in patients of Middle Eastern and North African ancestry residing in Ontario, Canada.
Mult Scler. 2020 Aug 11:1352458520948212. doi: 10.1177/1352458520948212.
PubMed Abstract available

MOSS BP, Mahajan KR, Bermel RA, Hellisz K, et al
Multiple sclerosis management during the COVID-19 pandemic.
Mult Scler. 2020 Aug 10:1352458520948231. doi: 10.1177/1352458520948231.
PubMed Abstract available

BROWNLEE WJ
COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?
Mult Scler. 2020 Aug 7:1352458520948211. doi: 10.1177/1352458520948211.
PubMed

WURM H, Attfield K, Iversen AK, Gold R, et al
Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient.
Mult Scler. 2020 Aug 7:1352458520943791. doi: 10.1177/1352458520943791.
PubMed Abstract available

DERSCH R, Wehrum T, Fahndrich S, Engelhardt M, et al
COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
Mult Scler. 2020 Aug 7:1352458520943783. doi: 10.1177/1352458520943783.
PubMed Abstract available

JAWORSKI MG 3RD, Fuchs TA, Dwyer MG, Wojcik C, et al
Conscientiousness and deterioration in employment status in multiple sclerosis over 3 years.
Mult Scler. 2020 Aug 6:1352458520946019. doi: 10.1177/1352458520946019.
PubMed Abstract available

GERALDES R, Jurynczyk M, Dos Passos GR, Pichler A, et al
The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease.
Mult Scler. 2020 Aug 6:1352458520943777. doi: 10.1177/1352458520943777.
PubMed Abstract available

GUISSET F, Lolli V, Bugli C, Perrotta G, et al
The central vein sign in multiple sclerosis patients with vascular comorbidities.
Mult Scler. 2020 Aug 4:1352458520943785. doi: 10.1177/1352458520943785.
PubMed Abstract available

ALEXANDER S, Peryer G, Gray E, Barkhof F, et al
Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping review.
Mult Scler. 2020 Aug 4:1352458520946005. doi: 10.1177/1352458520946005.
PubMed Abstract available

LIPP I, Foster C, Stickland R, Sgarlata E, et al
Predictors of training-related improvement in visuomotor performance in patients with multiple sclerosis: A behavioural and MRI study.
Mult Scler. 2020 Aug 4:1352458520943788. doi: 10.1177/1352458520943788.
PubMed Abstract available

ABBOUD H
Iatrogenic demyelinating disorders: New insights, new culprits.
Mult Scler. 2020;26:1129-1130.
PubMed

July 2020

RINGH MV, Hagemann-Jensen M, Needhamsen M, Kullberg S, et al
Methylome and transcriptome signature of bronchoalveolar cells from multiple sclerosis patients in relation to smoking.
Mult Scler. 2020 Jul 30:1352458520943768. doi: 10.1177/1352458520943768.
PubMed Abstract available

CORRIGENDUM to "Effectiveness of the transcutaneous tibial nerve stimulation and pelvic floor muscle training with biofeedback in women with multiple sclerosis for the management of overactive bladder".
Mult Scler. 2020 Jul 24:1352458520945512. doi: 10.1177/1352458520945512.
PubMed

SIMPSON-YAP S, Oddy WH, Taylor B, Lucas RM, et al
High Prudent diet factor score predicts lower relapse hazard in early multiple sclerosis.
Mult Scler. 2020 Jul 23:1352458520943087. doi: 10.1177/1352458520943087.
PubMed Abstract available

INOJOSA H, Ziemssen T
How to reduce the delay of diagnosing secondary progression in multiple sclerosis.
Mult Scler. 2020 Jul 22:1352458520943799. doi: 10.1177/1352458520943799.
PubMed

CONWAY DS, Thompson NR, Meng X, Johnson K, et al
Patient reported outcomes and performance metrics at diagnosis of secondary progressive multiple sclerosis.
Mult Scler. 2020 Jul 16:1352458520936214. doi: 10.1177/1352458520936214.
PubMed Abstract available

HUBBARD AL, Golla H, Lausberg H
What's in a name? That which we call Multiple Sclerosis Fatigue.
Mult Scler. 2020 Jul 16:1352458520941481. doi: 10.1177/1352458520941481.
PubMed Abstract available

PEETERS LM, Parciak T, Walton C, Geys L, et al
COVID-19 in people with multiple sclerosis: A global data sharing initiative.
Mult Scler. 2020 Jul 14:1352458520941485. doi: 10.1177/1352458520941485.
PubMed Abstract available

HIDALGO DE LA CRUZ M, Valsasina P, Gobbi C, Gallo A, et al
Longitudinal cortical thinning progression differs across multiple sclerosis phenotypes and is clinically relevant: A multicentre study.
Mult Scler. 2020 Jul 14:1352458520940548. doi: 10.1177/1352458520940548.
PubMed Abstract available

BARCELLOS LF, Horton M, Shao X, Bellesis KH, et al
A validation study for remote testing of cognitive function in multiple sclerosis.
Mult Scler. 2020 Jul 14:1352458520937385. doi: 10.1177/1352458520937385.
PubMed Abstract available

LOONSTRA FC, Hoitsma E, van Kempen ZL, Killestein J, et al
COVID-19 in multiple sclerosis: The Dutch experience.
Mult Scler. 2020 Jul 14:1352458520942198. doi: 10.1177/1352458520942198.
PubMed Abstract available

STORELLI L, Pagani E, Preziosa P, Filippi M, et al
Measurement of white matter fiber-bundle cross-section in multiple sclerosis using diffusion-weighted imaging.
Mult Scler. 2020 Jul 14:1352458520938999. doi: 10.1177/1352458520938999.
PubMed Abstract available

ABBATEMARCO JR, Griffin A, Jones NG, Hartman J, et al
Long-term outcomes of intrathecal baclofen in ambulatory multiple sclerosis patients: A single-center experience.
Mult Scler. 2020 Jul 14:1352458520936912. doi: 10.1177/1352458520936912.
PubMed Abstract available

WU P, Li R, Zhang W, Lu H, et al
Mendelian randomization analysis does not support a role for leptin in multiple sclerosis.
Mult Scler. 2020 Jul 14:1352458520938990. doi: 10.1177/1352458520938990.
PubMed

PINTER D, Khalil M, Pirpamer L, Damulina A, et al
Long-term course and morphological MRI correlates of cognitive function in multiple sclerosis.
Mult Scler. 2020 Jul 14:1352458520941474. doi: 10.1177/1352458520941474.
PubMed Abstract available

CROTEAU D, Tobenkin A, Brinker A, Kortepeter CM, et al
Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation.
Mult Scler. 2020 Jul 14:1352458520938354. doi: 10.1177/1352458520938354.
PubMed Abstract available

GERALDES R
Two-armed active comparator trials are unethical in pediatric multiple sclerosis - No.
Mult Scler. 2020 Jul 10:1352458520931784. doi: 10.1177/1352458520931784.
PubMed

WAUBANT E
Two-armed active comparator trials are unethical in paediatric multiple sclerosis - Commentary.
Mult Scler. 2020 Jul 10:1352458520936243. doi: 10.1177/1352458520936243.
PubMed

KRUPP LB, Charvet LE
Two-armed active comparator trials are unethical in pediatric multiple sclerosis - Yes.
Mult Scler. 2020 Jul 10:1352458520931796. doi: 10.1177/1352458520931796.
PubMed

CHITNIS T, Banwell B, Krupp L, Arnold DL, et al
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study.
Mult Scler. 2020 Jul 7:1352458520936934. doi: 10.1177/1352458520936934.
PubMed Abstract available

FITZGERALD KC, Morris B, Soroosh A, Balshi A, et al
Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosis-related fatigue.
Mult Scler. 2020 Jul 7:1352458520936226. doi: 10.1177/1352458520936226.
PubMed Abstract available

HACOHEN Y, Banwell B, Ciccarelli O
What does first-line therapy mean for paediatric multiple sclerosis in the current era?
Mult Scler. 2020 Jul 7:1352458520937644. doi: 10.1177/1352458520937644.
PubMed Abstract available

BSTEH G, Berek K, Hegen H, Altmann P, et al
Macular ganglion cell-inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis.
Mult Scler. 2020 Jul 2:1352458520935724. doi: 10.1177/1352458520935724.
PubMed Abstract available

THRUE C, Riemenschneider M, Hvid LG, Stenager E, et al
Time matters: Early-phase multiple sclerosis is accompanied by considerable impairments across multiple domains.
Mult Scler. 2020 Jul 2:1352458520936231. doi: 10.1177/1352458520936231.
PubMed Abstract available

June 2020

FEINSTEIN A, Meza C, Stefan C, Staines WR, et al
Discontinuing cannabis improves depression in people with multiple sclerosis: A short report.
Mult Scler. 2020 Jun 26:1352458520934070. doi: 10.1177/1352458520934070.
PubMed Abstract available

SIGNORI A, Boffa G, Bovis F, Mariottini A, et al
Prevalence of disability improvement as a potential outcome for multiple sclerosis trials.
Mult Scler. 2020 Jun 26:1352458520936236. doi: 10.1177/1352458520936236.
PubMed Abstract available

Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis.
Mult Scler. 2020 Jun 26:1352458520924594. doi: 10.1177/1352458520924594.
PubMed Abstract available

MEHNDIRATTA A, Treaba CA, Barletta V, Herranz E, et al
Characterization of thalamic lesions and their correlates in multiple sclerosis by ultra-high-field MRI.
Mult Scler. 2020 Jun 25:1352458520932804. doi: 10.1177/1352458520932804.
PubMed Abstract available

BOVE R, Rowles W, Zhao C, Anderson A, et al
A novel in-home digital treatment to improve processing speed in people with multiple sclerosis: A pilot study.
Mult Scler. 2020 Jun 25:1352458520930371. doi: 10.1177/1352458520930371.
PubMed Abstract available

WIENDL H, Spelman T, Butzkueven H, Kappos L, et al
Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program.
Mult Scler. 2020 Jun 24:1352458520926869. doi: 10.1177/1352458520926869.
PubMed Abstract available

GLUKHOVSKY L, Brandstadter R, Leavitt VM, Krieger S, et al
Hippocampal volume is more related to patient-reported memory than objective memory performance in early multiple sclerosis.
Mult Scler. 2020 Jun 22:1352458520922830. doi: 10.1177/1352458520922830.
PubMed Abstract available

SASTRE-GARRIGA J, Tintore M, Montalban X
Keeping standards of multiple sclerosis care through the COVID-19 pandemic.
Mult Scler. 2020 Jun 19:1352458520931785. doi: 10.1177/1352458520931785.
PubMed

LEVIN SN, Ezuma C, Levine L, Vargas WS, et al
Switching from natalizumab to ocrelizumab in patients with multiple sclerosis.
Mult Scler. 2020 Jun 19:1352458520927631. doi: 10.1177/1352458520927631.
PubMed

GHEZZI A, Banwell B, Bar-Or A, Chitnis T, et al
Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations.
Mult Scler. 2020 Jun 19:1352458520932798. doi: 10.1177/1352458520932798.
PubMed Abstract available

BHARGAVA P, Nogueras-Ortiz C, Kim S, Delgado-Peraza F, et al
Synaptic and complement markers in extracellular vesicles in multiple sclerosis.
Mult Scler. 2020 Jun 17:1352458520924590. doi: 10.1177/1352458520924590.
PubMed Abstract available

RICIGLIANO VA, Tonietto M, Palladino R, Poirion E, et al
Thalamic energy dysfunction is associated with thalamo-cortical tract damage in multiple sclerosis: A diffusion spectroscopy study.
Mult Scler. 2020 Jun 17:1352458520921362. doi: 10.1177/1352458520921362.
PubMed Abstract available

YAVARPOUR-BALI H, Ghasemi-Kasman M
The role of inflammasomes in multiple sclerosis.
Mult Scler. 2020 Jun 16:1352458520932776. doi: 10.1177/1352458520932776.
PubMed Abstract available

GHEZZI A, Amato MP, Edan G, Hartung HP, et al
The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges.
Mult Scler. 2020 Jun 16:1352458520930620. doi: 10.1177/1352458520930620.
PubMed Abstract available

LE M, Malpas C, Sharmin S, Horakova D, et al
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.
Mult Scler. 2020 Jun 15:1352458520926955. doi: 10.1177/1352458520926955.
PubMed Abstract available

IACOBAEUS E, Arrambide G, Pia Amato M, Derfuss T, et al
Aggressive multiple sclerosis (1): Towards a definition of the phenotype.
Mult Scler. 2020 Jun 12:1352458520925369. doi: 10.1177/1352458520925369.
PubMed Abstract available

ARRAMBIDE G, Iacobaeus E, Amato MP, Derfuss T, et al
Aggressive multiple sclerosis (2): Treatment.
Mult Scler. 2020 Jun 12:1352458520924595. doi: 10.1177/1352458520924595.
PubMed Abstract available

LIZAK N, Hodgkinson S, Butler E, Lechner-Scott J, et al
Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.
Mult Scler. 2020 Jun 12:1352458520921087. doi: 10.1177/1352458520921087.
PubMed Abstract available

POLAT DUNYA C, Tulek Z, Kurtuncu M, Panicker JN, et al
Effectiveness of the transcutaneous tibial nerve stimulation and pelvic floor muscle training with biofeedback in women with multiple sclerosis for the management of overactive bladder.
Mult Scler. 2020 Jun 9:1352458520926666. doi: 10.1177/1352458520926666.
PubMed Abstract available

SOLARI A, Oliver D
Palliative care in multiple sclerosis: European guideline.
Mult Scler. 2020 Jun 9:1352458520926467. doi: 10.1177/1352458520926467.
PubMed

XU Y, Hiyoshi A, Brand JS, Smith KA, et al
Higher body mass index at ages 16 to 20 years is associated with increased risk of a multiple sclerosis diagnosis in subsequent adulthood among men.
Mult Scler. 2020 Jun 8:1352458520928061. doi: 10.1177/1352458520928061.
PubMed Abstract available

BROWN J, Quattrochi B, Everett C, Hong BY, et al
Gut commensals, dysbiosis, and immune response imbalance in the pathogenesis of multiple sclerosis.
Mult Scler. 2020 Jun 8:1352458520928301. doi: 10.1177/1352458520928301.
PubMed Abstract available

CELIUS EG
Breastfeeding and treatment of multiple sclerosis.
Mult Scler. 2020 Jun 8:1352458520931786. doi: 10.1177/1352458520931786.
PubMed

PIHL-JENSEN G, Wanscher B, Frederiksen JL
Predictive value of optical coherence tomography, multifocal visual evoked potentials, and full-field visual evoked potentials of the fellow, non-symptomatic eye for subsequent multiple sclerosis development in patients with acute optic neuritis.
Mult Scler. 2020 Jun 8:1352458520917924. doi: 10.1177/1352458520917924.
PubMed Abstract available

ROJAS JI, Patrucco L, Alonso R, Garcea O, et al
Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis: Multicenter study in Argentina.
Mult Scler. 2020 Jun 2:1352458520924586. doi: 10.1177/1352458520924586.
PubMed Abstract available

OH J, Chen M, Cybulsky K, Suthiphosuwan S, et al
Five-year longitudinal changes in quantitative spinal cord MRI in multiple sclerosis.
Mult Scler. 2020 Jun 1:1352458520923970. doi: 10.1177/1352458520923970.
PubMed Abstract available

COSTELLO F, Petzold A
Weighting evidence in MS: Obesity and neurodegeneration.
Mult Scler. 2020;26:748-750.
PubMed

BOYKO A
Radiologically isolated syndrome with oligoclonal bands in CSF (RIS + OCB) can be classified as high MS risk group.
Mult Scler. 2020;26:869-870.
PubMed

DE STEFANO N
Response to Dr Boyko's letter: 'Radiologically isolated syndrome with oligoclonal bands in CSF (RIS + OCB) can be classified as highly MS-risk group'.
Mult Scler. 2020;26:871.
PubMed

VAN DER WALT A
Addressing the treatment gap in MS-associated tremor: A new door opens.
Mult Scler. 2020;26:858.
PubMed

May 2020

VARGAS WS, Noble KG, Banwell B, De Jager P, et al
The educational impact of childhood-onset multiple sclerosis: Why assessing academic achievement is imperative.
Mult Scler. 2020 May 28:1352458520923946. doi: 10.1177/1352458520923946.
PubMed Abstract available

VON WYL V, Benkert P, Moser A, Lorscheider J, et al
Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate.
Mult Scler. 2020 May 28:1352458520918489. doi: 10.1177/1352458520918489.
PubMed Abstract available

CARANDINI T, Pietroboni AM, Sacchi L, De Riz MA, et al
Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression.
Mult Scler. 2020 May 28:1352458520926459. doi: 10.1177/1352458520926459.
PubMed

PASQUA G, Tommasin S, Bharti K, Ruggieri S, et al
Resting-state functional connectivity of anterior and posterior cerebellar lobes is altered in multiple sclerosis.
Mult Scler. 2020 May 28:1352458520922770. doi: 10.1177/1352458520922770.
PubMed Abstract available

AYRIGNAC X, Larochelle C, Keezer M, Roger E, et al
Frailty in ageing persons with multiple sclerosis.
Mult Scler. 2020 May 27:1352458520923945. doi: 10.1177/1352458520923945.
PubMed Abstract available

CORONADO I, Gabr RE, Narayana PA
Deep learning segmentation of gadolinium-enhancing lesions in multiple sclerosis.
Mult Scler. 2020 May 22:1352458520921364. doi: 10.1177/1352458520921364.
PubMed Abstract available

WANG FM, Davis MF, Briggs FB
Predicting self-reported depression after the onset of multiple sclerosis using genetic and non-genetic factors.
Mult Scler. 2020 May 18:1352458520921073. doi: 10.1177/1352458520921073.
PubMed Abstract available

VALBURG C, Sonti A, Stern JN, Najjar S, et al
Dietary factors in experimental autoimmune encephalomyelitis and multiple sclerosis: A comprehensive review.
Mult Scler. 2020 May 14:1352458520923955. doi: 10.1177/1352458520923955.
PubMed Abstract available

BRUIJSTENS AL, Blok KM, Smolders J, Wokke BH, et al
Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment.
Mult Scler. 2020 May 14:1352458520921367. doi: 10.1177/1352458520921367.
PubMed

KILJAN S, Preziosa P, Jonkman LE, van de Berg WD, et al
Cortical axonal loss is associated with both gray matter demyelination and white matter tract pathology in progressive multiple sclerosis: Evidence from a combined MRI-histopathology study.
Mult Scler. 2020 May 11:1352458520918978. doi: 10.1177/1352458520918978.
PubMed Abstract available

GHARAKHANLOU R, Wesselmann L, Rademacher A, Lampit A, et al
Exercise training and cognitive performance in persons with multiple sclerosis: A systematic review and multilevel meta-analysis of clinical trials.
Mult Scler. 2020 May 11:1352458520917935. doi: 10.1177/1352458520917935.
PubMed Abstract available

LUNEMANN JD, Diaz-Diaz J, Stankoff B, Young C, et al
Highlights from the 2019 European Congress on Treatment and Research in Multiple Sclerosis (ECTRIMS 2019).
Mult Scler. 2020 May 4:1352458520918377. doi: 10.1177/1352458520918377.
PubMed Abstract available

BOSE G, Thebault S, Rush CA, Atkins HL, et al
Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective.
Mult Scler. 2020 May 4:1352458520917936. doi: 10.1177/1352458520917936.
PubMed Abstract available

LAMBE J, Saidha S, Bermel RA
Optical coherence tomography and multiple sclerosis: Update on clinical application and role in clinical trials.
Mult Scler. 2020;26:624-639.
PubMed Abstract available

HARTUNG HP, Mares J, Barnett MH
Alemtuzumab: Rare serious adverse events of a high-efficacy drug.
Mult Scler. 2020;26:737-740.
PubMed

KRIEGER SC, Sumowski JF
Toward biologically meaningful categories of MS-related fatigue.
Mult Scler. 2020;26:620-621.
PubMed

PROSCHMANN U, Sehr T, Akgun K, Ziemssen T, et al
Letter to the editor regarding "Therapeutic drug monitoring of natalizumab".
Mult Scler. 2020;26:741-742.
PubMed

April 2020

FOX E, Lovett-Racke AE, Gormley M, Liu Y, et al
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
Mult Scler. 2020 Apr 30:1352458520918375. doi: 10.1177/1352458520918375.
PubMed Abstract available

KALB R, Brown TR, Coote S, Costello K, et al
Exercise and lifestyle physical activity recommendations for people with multiple sclerosis throughout the disease course.
Mult Scler. 2020 Apr 23:1352458520915629. doi: 10.1177/1352458520915629.
PubMed Abstract available

AHRABIAN D, Neill L, Bell R, Leary SM, et al
Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.
Mult Scler. 2020 Apr 16:1352458519855725. doi: 10.1177/1352458519855725.
PubMed Abstract available

FILIPPATOU AG, Lambe J, Sotirchos ES, Fitzgerald KC, et al
Association of body mass index with longitudinal rates of retinal atrophy in multiple sclerosis.
Mult Scler. 2020 Apr 16:1352458519900942. doi: 10.1177/1352458519900942.
PubMed Abstract available

UHER T, McComb M, Galkin S, Srpova B, et al
Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis.
Mult Scler. 2020 Apr 7:1352458520912379. doi: 10.1177/1352458520912379.
PubMed Abstract available

YUSUF F, Wijnands JM, Kingwell E, Zhu F, et al
Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome.
Mult Scler. 2020 Apr 6:1352458520908163. doi: 10.1177/1352458520908163.
PubMed Abstract available

BELBASIS L, Bellou V, Evangelou E, Tzoulaki I, et al
Environmental factors and risk of multiple sclerosis: Findings from meta-analyses and Mendelian randomization studies.
Mult Scler. 2020;26:397-404.
PubMed Abstract available

SOLOMON AJ
Progress towards a diagnostic biomarker for MS: Central vein sign.
Mult Scler. 2020;26:394-396.
PubMed

March 2020

HEALY BC, Barker L, Bakshi R, Benedict RHB, et al
Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis.
Mult Scler. 2020 Mar 31:1352458520913439. doi: 10.1177/1352458520913439.
PubMed Abstract available

TREMLETT H, Marrie RA
The multiple sclerosis prodrome: Emerging evidence, challenges, and opportunities.
Mult Scler. 2020 Mar 31:1352458520914844. doi: 10.1177/1352458520914844.
PubMed Abstract available

MOTL RW, Sandroff BM, Benedict RH, Hubbard EM, et al
Do subcortical gray matter volumes and aerobic capacity account for cognitive-motor coupling in multiple sclerosis?
Mult Scler. 2020 Mar 31:1352458520914822. doi: 10.1177/1352458520914822.
PubMed Abstract available

DEMORTIERE S, Rico A, Maarouf A, Boutiere C, et al
Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis.
Mult Scler. 2020 Mar 23:1352458520912637. doi: 10.1177/1352458520912637.
PubMed Abstract available

JACOBS BM, Giovannoni G, Cuzick J, Dobson R, et al
Systematic review and meta-analysis of the association between Epstein-Barr virus, multiple sclerosis and other risk factors.
Mult Scler. 2020 Mar 23:1352458520907901. doi: 10.1177/1352458520907901.
PubMed Abstract available

DADAR M, Narayanan S, Arnold DL, Collins DL, et al
Conversion of diffusely abnormal white matter to focal lesions is linked to progression in secondary progressive multiple sclerosis.
Mult Scler. 2020 Mar 23:1352458520912172. doi: 10.1177/1352458520912172.
PubMed Abstract available

OTURAI DB, Bach Sondergaard H, Koch-Henriksen N, Andersen C, et al
Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis.
Mult Scler. 2020 Mar 23:1352458520912500. doi: 10.1177/1352458520912500.
PubMed Abstract available

PEREZ T, Rico A, Boutiere C, Maarouf A, et al
Comparison of rituximab originator (MabThera((R))) to biosimilar (Truxima((R))) in patients with multiple sclerosis.
Mult Scler. 2020 Mar 17:1352458520912170. doi: 10.1177/1352458520912170.
PubMed Abstract available

SOLOMON AJ, Pettigrew R, Naismith RT, Chahin S, et al
Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteria.
Mult Scler. 2020 Mar 12:1352458520910496. doi: 10.1177/1352458520910496.
PubMed Abstract available

BERTOLI M, Tecchio F
Fatigue in multiple sclerosis: Does the functional or structural damage prevail?
Mult Scler. 2020 Mar 12:1352458520912175. doi: 10.1177/1352458520912175.
PubMed Abstract available

DALGAS U, Hvid LG, Kwakkel G, Motl RW, et al
Moving exercise research in multiple sclerosis forward (the MoXFo initiative): Developing consensus statements for research.
Mult Scler. 2020 Mar 12:1352458520910360. doi: 10.1177/1352458520910360.
PubMed Abstract available

SMITH KA, Burkill S, Hiyoshi A, Olsson T, et al
Comorbid disease burden among MS patients 1968-2012: A Swedish register-based cohort study.
Mult Scler. 2020 Mar 12:1352458520910497. doi: 10.1177/1352458520910497.
PubMed Abstract available

NG HS, Kingwell E, Zhu F, Zhang T, et al
Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study.
Mult Scler. 2020 Mar 6:1352458520910500. doi: 10.1177/1352458520910500.
PubMed Abstract available

ABDEL-MANNAN O, Cortese R, Wassmer E, Hemingway C, et al
Primary progressive multiple sclerosis presenting under the age of 18 years: Fact or fiction?
Mult Scler. 2020 Mar 3:1352458520910361. doi: 10.1177/1352458520910361.
PubMed Abstract available

LEITE MI, Sato DK
MOG-antibody-associated disease is different from MS and NMOSD and should be considered as a distinct disease entity - Yes.
Mult Scler. 2020;26:272-274.
PubMed

COBO-CALVO A, Marignier R
MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity - No.
Mult Scler. 2020;26:274-276.
PubMed

DURAND-DUBIEF F, Marignier R, Berthezene Y, Cottin J, et al
Spontaneous multiple cervical artery dissections after alemtuzumab.
Mult Scler. 2020;26:381-383.
PubMed Abstract available

CHIARAVALLOTI ND, Moore NB, DeLuca J
The efficacy of the modified Story Memory Technique in progressive MS.
Mult Scler. 2020;26:354-362.
PubMed Abstract available

February 2020

POVOLO CA, Reid JN, Shariff SZ, Welk B, et al
Concussion in adolescence and the risk of multiple sclerosis: A retrospective cohort study.
Mult Scler. 2020 Feb 24:1352458520908037. doi: 10.1177/1352458520908037.
PubMed Abstract available

FONDERICO M, Biagioli T, Lanzilao L, Bellinvia A, et al
Prognostic role of intrathecal IgM synthesis in multiple sclerosis: Results from a clinical series.
Mult Scler. 2020 Feb 24:1352458520907913. doi: 10.1177/1352458520907913.
PubMed Abstract available

HORISBERGER A, Pantazou V, Cuendet G, Ribi C, et al
ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis.
Mult Scler. 2020 Feb 21:1352458519895449. doi: 10.1177/1352458519895449.
PubMed Abstract available

BIGAUT K, Lambert C, Kremer L, Lebrun C, et al
Atypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders.
Mult Scler. 2020 Feb 20:1352458520906995. doi: 10.1177/1352458520906995.
PubMed Abstract available

MAHLANZA TD, Manieri MC, Klawiter EC, Solomon AJ, et al
Prospective growth and developmental outcomes in infants born to mothers with multiple sclerosis.
Mult Scler. 2020 Feb 17:1352458520904545. doi: 10.1177/1352458520904545.
PubMed Abstract available

MCKEON A, Zekeridou A
Autoimmune encephalitis management: MS centers and beyond.
Mult Scler. 2020 Feb 13:1352458520905485. doi: 10.1177/1352458520905485.
PubMed Abstract available

SERRA A, Petzold A
Can stability of visual fixation be a measure for disability in multiple sclerosis?
Mult Scler. 2020 Feb 7:1352458520903296. doi: 10.1177/1352458520903296.
PubMed

SHEEHY CK, Bensinger ES, Romeo A, Rani L, et al
Fixational microsaccades: A quantitative and objective measure of disability in multiple sclerosis.
Mult Scler. 2020 Feb 7:1352458519894712. doi: 10.1177/1352458519894712.
PubMed Abstract available

BSTEH G, Berger T
Commentary on "Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis".
Mult Scler. 2020 Feb 7:1352458520904546. doi: 10.1177/1352458520904546.
PubMed

SON M, McEwan L, Ubaidat M, Bovell K, et al
Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis.
Mult Scler. 2020 Feb 7:1352458519900961. doi: 10.1177/1352458519900961.
PubMed Abstract available

BISTROM M, Hultdin J, Andersen O, Alonso-Magdalena L, et al
Leptin levels are associated with multiple sclerosis risk.
Mult Scler. 2020 Feb 7:1352458520905033. doi: 10.1177/1352458520905033.
PubMed Abstract available

BOUVET L, Chassard D
Is neuraxial anesthesia not associated with increased risk of post-partum relapses in multiple sclerosis? More precise assessment is required.
Mult Scler. 2020 Feb 5:1352458519898344. doi: 10.1177/1352458519898344.
PubMed

MARIOTTINI A, Filippini S, Innocenti C, Forci B, et al
Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis.
Mult Scler. 2020 Feb 3:1352458520902392. doi: 10.1177/1352458520902392.
PubMed Abstract available

ABSINTA M, Ontaneda D
Controversial association between leptomeningeal enhancement and demyelinated cortical lesions in multiple sclerosis.
Mult Scler. 2020;26:135-136.
PubMed

THOMPSON AJ, Cohen JA, Kim HJ, Geurts J, et al
MSJ 2020 - Editorial comment.
Mult Scler. 2020;26:134.
PubMed

LUBLIN F
Real-world studies provide reliable comparisons of disease modifying therapies in MS - Commentary.
Mult Scler. 2020;26:163-164.
PubMed

SORMANI MP
Real-world studies provide reliable comparisons of disease modifying therapies in MS - No.
Mult Scler. 2020;26:161-162.
PubMed

KALINCIK T
Real-world studies provide reliable comparisons of disease modifying therapies in MS - Yes.
Mult Scler. 2020;26:159-161.
PubMed

January 2020

CHARABATI M, Donkers SJ, Kirkland MC, Osborne LC, et al
A critical analysis of helminth immunotherapy in multiple sclerosis.
Mult Scler. 2020 Jan 23:1352458519899040. doi: 10.1177/1352458519899040.
PubMed Abstract available

PALOTAI M, Cavallari M, Healy BC, Guttmann CR, et al
A novel classification of fatigue in multiple sclerosis based on longitudinal assessments.
Mult Scler. 2020 Jan 23:1352458519898112. doi: 10.1177/1352458519898112.
PubMed Abstract available

BENEDICT RH, Pol J, Yasin F, Hojnacki D, et al
Recovery of cognitive function after relapse in multiple sclerosis.
Mult Scler. 2020 Jan 23:1352458519898108. doi: 10.1177/1352458519898108.
PubMed Abstract available

CHITNIS T, Prat A
A roadmap to precision medicine for multiple sclerosis.
Mult Scler. 2020 Jan 22:1352458519881558. doi: 10.1177/1352458519881558.
PubMed Abstract available

BOSE G, Freedman MS
Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment.
Mult Scler. 2020 Jan 22:1352458519887324. doi: 10.1177/1352458519887324.
PubMed Abstract available

MYCKO MP, Baranzini SE
microRNA and exosome profiling in multiple sclerosis.
Mult Scler. 2020 Jan 22:1352458519879303. doi: 10.1177/1352458519879303.
PubMed Abstract available

VOSKUHL RR
The effect of sex on multiple sclerosis risk and disease progression.
Mult Scler. 2020 Jan 22:1352458519892491. doi: 10.1177/1352458519892491.
PubMed Abstract available

PATSOPOULOS NA, De Jager PL
Genetic and gene expression signatures in multiple sclerosis.
Mult Scler. 2020 Jan 22:1352458519898332. doi: 10.1177/1352458519898332.
PubMed Abstract available

BHARGAVA P, Anthony D
Metabolomics in multiple sclerosis disease course and progression.
Mult Scler. 2020 Jan 22:1352458519876020. doi: 10.1177/1352458519876020.
PubMed Abstract available

KISTER I, Kantarci OH
Multiple Sclerosis Severity Score: Concept and applications.
Mult Scler. 2020 Jan 22:1352458519880125. doi: 10.1177/1352458519880125.
PubMed Abstract available

CARNERO CONTENTTI E, Giachello S, Correale J
Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients.
Mult Scler. 2020 Jan 21:1352458519898590. doi: 10.1177/1352458519898590.
PubMed Abstract available

SRPOVA B, Uher T, Hrnciarova T, Barro C, et al
Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis.
Mult Scler. 2020 Jan 21:1352458519901272. doi: 10.1177/1352458519901272.
PubMed Abstract available

CORTESE R, Tur C, Prados F, Schneider T, et al
Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis.
Mult Scler. 2020 Jan 21:1352458519900971. doi: 10.1177/1352458519900971.
PubMed Abstract available

MCDONELL J, Costello K, Laurson-Doube J, Rijke N, et al
World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application.
Mult Scler. 2020 Jan 16:1352458519898340. doi: 10.1177/1352458519898340.
PubMed Abstract available

SALTER A, Fox RJ, Tyry T, Cutter G, et al
New applications for independent activities of daily living in measuring disability in multiple sclerosis.
Mult Scler. 2020 Jan 14:1352458519898591. doi: 10.1177/1352458519898591.
PubMed Abstract available

WARNKE C, Hartung HP
Big data in MS-What can we learn from large international observational studies such as MSBase?
Mult Scler. 2020;26:4-5.
PubMed

REDDEL SW
Clinical commentary on 'Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis'.
Mult Scler. 2020;26:126-127.
PubMed

VUKUSIC S, Casey R, Rollot F, Brochet B, et al
Observatoire Francais de la Sclerose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France.
Mult Scler. 2020;26:118-122.
PubMed Abstract available

MELI R, Roccatagliata L, Capello E, Bruschi N, et al
Ecological impact of isolated cognitive relapses in MS.
Mult Scler. 2020;26:114-117.
PubMed Abstract available

December 2019

CROUSE DL, Foroughi I, Gupta N
Neighbourhood environments and the risk of hospital admission for cardiometabolic and mental health comorbidities in multiple sclerosis: A population cohort analysis using linked administrative data.
Mult Scler. 2019 Dec 20:1352458519895985. doi: 10.1177/1352458519895985.
PubMed Abstract available

COULOUME L, Barbin L, Leray E, Wiertlewski S, et al
High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice.
Mult Scler. 2019 Dec 17:1352458519894713. doi: 10.1177/1352458519894713.
PubMed Abstract available

KALKERS NF, Galan I, Kerbrat A, Tacchino A, et al
Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries.
Mult Scler. 2019 Dec 17:1352458519895450. doi: 10.1177/1352458519895450.
PubMed Abstract available

KVISTAD SAS, Lehmann AK, Trovik LH, Kristoffersen EK, et al
Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway.
Mult Scler. 2019 Dec 13:1352458519893926. doi: 10.1177/1352458519893926.
PubMed Abstract available

HOLTON KF, Kirkland AE
Moving past antioxidant supplementation for the dietary treatment of multiple sclerosis.
Mult Scler. 2019 Dec 11:1352458519893925. doi: 10.1177/1352458519893925.
PubMed Abstract available

RAHNAMA'I MS
Neuromodulation for functional bladder disorders in patients with multiple sclerosis.
Mult Scler. 2019 Dec 9:1352458519894714. doi: 10.1177/1352458519894714.
PubMed Abstract available

BISECCO A, Capuano R, Caiazzo G, d'Ambrosio A, et al
Regional changes in thalamic shape and volume are related to cognitive performance in multiple sclerosis.
Mult Scler. 2019 Dec 3:1352458519892552. doi: 10.1177/1352458519892552.
PubMed Abstract available

HARDY TA
Regulatory B cells: The key to post-alemtuzumab rebound phenomena in multiple sclerosis?
Mult Scler. 2019;25:1945-1946.
PubMed

November 2019

GONZALEZ CAMPO C, Salamone PC, Rodriguez-Arriagada N, Richter F, et al
Fatigue in multiple sclerosis is associated with multimodal interoceptive abnormalities.
Mult Scler. 2019 Nov 28:1352458519888881. doi: 10.1177/1352458519888881.
PubMed Abstract available

COHEN JA, Trojano M, Mowry EM, Uitdehaag BM, et al
Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment.
Mult Scler. 2019 Nov 28:1352458519892555. doi: 10.1177/1352458519892555.
PubMed Abstract available

WALLACH AI, Waltz M, Casper TC, Aaen G, et al
Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline.
Mult Scler. 2019 Nov 28:1352458519891984. doi: 10.1177/1352458519891984.
PubMed Abstract available

LI CMF, Hung PS, Chu PP, Tohyama S, et al
Trigeminal neuralgia associated with multiple sclerosis: A multimodal assessment of brainstem plaques and response to Gamma Knife radiosurgery.
Mult Scler. 2019 Nov 26:1352458519886070. doi: 10.1177/1352458519886070.
PubMed Abstract available

COMI G, Alroughani R, Boster AL, Bass AD, et al
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
Mult Scler. 2019 Nov 25:1352458519888610. doi: 10.1177/1352458519888610.
PubMed Abstract available

KIM JE, Park SH, Han K, Kim HJ, et al
Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea.
Mult Scler. 2019 Nov 21:1352458519888609. doi: 10.1177/1352458519888609.
PubMed Abstract available

BRANDSTADTER R, Fabian M, Leavitt VM, Krieger S, et al
Word-finding difficulty is a prevalent disease-related deficit in early multiple sclerosis.
Mult Scler. 2019 Nov 19:1352458519881760. doi: 10.1177/1352458519881760.
PubMed Abstract available

BAETGE SJ, Filser M, Renner A, Ullrich S, et al
On the validity of single tests, two-test combinations and the full Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in detecting patients with cognitive impairment.
Mult Scler. 2019 Nov 19:1352458519887897. doi: 10.1177/1352458519887897.
PubMed Abstract available

ZURAWSKI J, Tauhid S, Chu R, Khalid F, et al
7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions.
Mult Scler. 2019 Nov 12:1352458519885106. doi: 10.1177/1352458519885106.
PubMed Abstract available

PELLEGRINI F, Copetti M, Sormani MP, Bovis F, et al
Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling.
Mult Scler. 2019 Nov 5:1352458519887343. doi: 10.1177/1352458519887343.
PubMed Abstract available

CORDANI C, Valsasina P, Preziosa P, Meani A, et al
Action observation training promotes motor improvement and modulates functional network dynamic connectivity in multiple sclerosis.
Mult Scler. 2019 Nov 5:1352458519887332. doi: 10.1177/1352458519887332.
PubMed Abstract available

BOESEN F, Norgaard M, Skjerbaek AG, Rasmussen PV, et al
Can inpatient multidisciplinary rehabilitation improve health-related quality of life in MS patients on the long term - The Danish MS Hospitals Rehabilitation Study.
Mult Scler. 2019 Nov 5:1352458519884244. doi: 10.1177/1352458519884244.
PubMed Abstract available

COLLORONE S, Cawley N, Grussu F, Prados F, et al
Reduced neurite density in the brain and cervical spinal cord in relapsing-remitting multiple sclerosis: A NODDI study.
Mult Scler. 2019 Nov 4:1352458519885107. doi: 10.1177/1352458519885107.
PubMed Abstract available

MILO R, Korczyn AD, Manouchehri N, Stuve O, et al
The temporal and causal relationship between inflammation and neurodegeneration in multiple sclerosis.
Mult Scler. 2019 Nov 4:1352458519886943. doi: 10.1177/1352458519886943.
PubMed Abstract available

NAISMITH RT, Wolinsky JS, Wundes A, LaGanke C, et al
Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Mult Scler. 2019 Nov 4:1352458519881761. doi: 10.1177/1352458519881761.
PubMed Abstract available

KUHLE J, Plavina T, Barro C, Disanto G, et al
Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.
Mult Scler. 2019 Nov 4:1352458519885613. doi: 10.1177/1352458519885613.
PubMed Abstract available

VAN WIJMEERSCH B, Singer BA, Boster A, Broadley S, et al
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Mult Scler. 2019 Nov 1:1352458519881759. doi: 10.1177/1352458519881759.
PubMed Abstract available

MOSTERT JP, De Keyser J
Response to Grech et al.: FLOUX-PMS study sample considerations.
Mult Scler. 2019;25:1820-1821.
PubMed

GRECH LB, Butler E, Stuckey S, Hester R, et al
Letter to the editor: FLOUX-PMS study sample considerations.
Mult Scler. 2019;25:1819-1820.
PubMed

October 2019

RYAN JM, Fortune J, Stennett A, Kilbride C, et al
Safety, feasibility, acceptability and effects of a behaviour-change intervention to change physical activity behaviour among people with multiple sclerosis: Results from the iStep-MS randomised controlled trial.
Mult Scler. 2019 Oct 31:1352458519886231. doi: 10.1177/1352458519886231.
PubMed Abstract available

LEAVITT VM, Riley CS, De Jager PL, Bloom S, et al
eSupport: Feasibility trial of telehealth support group participation to reduce loneliness in multiple sclerosis.
Mult Scler. 2019 Oct 31:1352458519884241. doi: 10.1177/1352458519884241.
PubMed Abstract available

ZHOU Y, Claflin SB, Stankovich J, van der Mei I, et al
Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.
Mult Scler. 2019 Oct 31:1352458519881994. doi: 10.1177/1352458519881994.
PubMed Abstract available

CLARKE MA, Samaraweera AP, Falah Y, Pitiot A, et al
Single Test to ARrive at Multiple Sclerosis (STAR-MS) diagnosis: A prospective pilot study assessing the accuracy of the central vein sign in predicting multiple sclerosis in cases of diagnostic uncertainty.
Mult Scler. 2019 Oct 31:1352458519882282. doi: 10.1177/1352458519882282.
PubMed Abstract available

BSTEH G, Berek K, Hegen H, Teuchner B, et al
Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis.
Mult Scler. 2019 Oct 31:1352458519882279. doi: 10.1177/1352458519882279.
PubMed Abstract available

WOJCIK CM, Beier M, Costello K, DeLuca J, et al
Computerized neuropsychological assessment devices in multiple sclerosis: A systematic review.
Mult Scler. 2019 Oct 22:1352458519879094. doi: 10.1177/1352458519879094.
PubMed Abstract available

CHITNIS T
Serum NFL levels should be used to monitor multiple sclerosis evolution - Commentary.
Mult Scler. 2019 Oct 18:1352458519880471. doi: 10.1177/1352458519880471.
PubMed

MYHR KM, Torkildsen O
Serum NFL levels should be used to monitor multiple sclerosis evolution - No.
Mult Scler. 2019 Oct 18:1352458519872891. doi: 10.1177/1352458519872891.
PubMed

LEPPERT D, Kuhle J
Serum NfL levels should be used to monitor multiple sclerosis evolution - Yes.
Mult Scler. 2019 Oct 18:1352458519872921. doi: 10.1177/1352458519872921.
PubMed

JOHANSSON S, Ytterberg C, Gottberg K, Holmqvist LW, et al
Participation in social/lifestyle activities in people with multiple sclerosis: Changes across 10 years and predictors of sustained participation.
Mult Scler. 2019 Oct 17:1352458519881991. doi: 10.1177/1352458519881991.
PubMed Abstract available

MANEZ-MIRO JU, Martinez-Fernandez R, Del Alamo M, Pineda-Pardo JA, et al
Focused ultrasound thalamotomy for multiple sclerosis-associated tremor.
Mult Scler. 2019 Oct 16:1352458519861597. doi: 10.1177/1352458519861597.
PubMed Abstract available

JAKIMOVSKI D, Zivadinov R, Ramanthan M, Hagemeier J, et al
Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.
Mult Scler. 2019 Oct 15:1352458519881428. doi: 10.1177/1352458519881428.
PubMed Abstract available

DAMASCENO A, Pimentel-Silva LR, Damasceno BP, Cendes F, et al
Cognitive trajectories in relapsing-remitting multiple sclerosis: A longitudinal 6-year study.
Mult Scler. 2019 Oct 11:1352458519878685. doi: 10.1177/1352458519878685.
PubMed Abstract available

BIANCHI A, Ciccarelli O
Daclizumab-induced encephalitis in multiple sclerosis.
Mult Scler. 2019;25:1557-1559.
PubMed

IGHANI M, Jonas S, Izbudak I, Choi S, et al
No association between cortical lesions and leptomeningeal enhancement on 7-Tesla MRI in multiple sclerosis.
Mult Scler. 2019 Oct 1:1352458519876037. doi: 10.1177/1352458519876037.
PubMed Abstract available

GRYTTEN N, Myhr KM, Celius EG, Benjaminsen E, et al
Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study.
Mult Scler. 2019 Oct 1:1352458519877244. doi: 10.1177/1352458519877244.
PubMed Abstract available

ZECCA C, Bovis F, Novi G, Capobianco M, et al
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
Mult Scler. 2019 Oct 1:1352458519872889. doi: 10.1177/1352458519872889.
PubMed Abstract available

MACARON G, Ontaneda D
Clinical commentary on "Warts and all: Fingolimod and unusual HPV associated lesions".
Mult Scler. 2019;25:1550-1552.
PubMed

BERGER JR
PML with dimethyl fumarate-No role for natalizumab?
Mult Scler. 2019;25:1686-1687.
PubMed

August 2019

KILLESTEIN J, van Oosten B
Emerging safety issues in alemtuzumab-treated MS patients.
Mult Scler. 2019;25:1206-1208.
PubMed

July 2019

WARNKE C, Hartung HP
Challenging a concept: Pulsed treatment regimen-No risk of PML?
Mult Scler. 2019;25:1076-1078.
PubMed

GEREVINI S, Capra R, Bertoli D, Sottini A, et al
Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy.
Mult Scler. 2019;25:1196-1201.
PubMed Abstract available

PREZIOSA P, Rocca MA, Filippi M
PET is necessary to make the next step forward in understanding MS pathophysiology - No.
Mult Scler. 2019;25:1088-1090.
PubMed

BODINI B, Stankoff B
PET is necessary to make the next step forward in understanding MS pathophysiology - Yes.
Mult Scler. 2019;25:1086-1087.
PubMed

COMBES B, Kerbrat A, Ferre JC, Callot V, et al
Focal and diffuse cervical spinal cord damage in patients with early relapsing-remitting MS: A multicentre magnetisation transfer ratio study.
Mult Scler. 2019;25:1113-1123.
PubMed Abstract available

KANG Y, Gauthier SA
PET is necessary to make the next step forward in understanding MS pathophysiology - Commentary.
Mult Scler. 2019;25:1090-1091.
PubMed

June 2019

GHEZZI L, Cantoni C, Cignarella F, Bollman B, et al
T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients.
Mult Scler. 2019 Jun 25:1352458519852092. doi: 10.1177/1352458519852092.
PubMed Abstract available

MESCHERIAKOVA JY, Verkerk J, Amin N, Uitterlinden AG, et al
Response to Vilarino-Guell et al.
Mult Scler. 2019;25:1013-1015.
PubMed

SCALFARI A
MS progression is predominantly driven by age-related mechanisms - YES.
Mult Scler. 2019;25:902-904.
PubMed

MCGINLEY M, Ontaneda D
MS progression is predominantly driven by age-related mechanisms - NO.
Mult Scler. 2019;25:904-906.
PubMed

ZEYDAN B, Kantarci OH
MS progression is predominantly driven by age-related mechanisms - Commentary.
Mult Scler. 2019;25:906-908.
PubMed

May 2019

FAZEKAS F
Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions - Commentary.
Mult Scler. 2019;25:770-771.
PubMed

SOLOMON AJ
Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions - Yes.
Mult Scler. 2019;25:766-768.
PubMed

BROWNLEE WJ
Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions - No.
Mult Scler. 2019;25:768-770.
PubMed

TRIPLETT J, Vijayan S, Prince R, Kermode A, et al
Dimethyl fumarate-associated transient bone marrow oedema syndrome.
Mult Scler. 2019;25:876-879.
PubMed Abstract available

ROSATO R, Testa S, Bertolotto A, Scavelli F, et al
eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54.
Mult Scler. 2019;25:856-866.
PubMed Abstract available

GOODIN DS, Reder AT, Traboulsee AL, Li DK, et al
Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.
Mult Scler. 2019;25:837-847.
PubMed Abstract available

DUROZARD P, Maarouf A, Boutiere C, Ruet A, et al
Efficacy of rituximab in refractory RRMS.
Mult Scler. 2019;25:828-836.
PubMed Abstract available

April 2019

LAVIE C, Rollot F, Durand-Dubief F, Marignier R, et al
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS.
Mult Scler. 2019;25:591-600.
PubMed Abstract available

BUCK D, Andlauer TF, Igl W, Wicklein EM, et al
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.
Mult Scler. 2019;25:565-573.
PubMed Abstract available

HYUN JW, Huh SY, Shin HJ, Woodhall M, et al
Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis.
Mult Scler. 2019;25:585-590.
PubMed Abstract available

ZELEK WM, Watkins LM, Howell OW, Evans R, et al
Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59.
Mult Scler. 2019;25:523-531.
PubMed Abstract available

MANOUSAKI D, Richards JB
Vitamin D deficiency is an etiological factor for MS - Yes.
Mult Scler. 2019;25:637-639.
PubMed

LANGER-GOULD A, Lucas RM
Vitamin D deficiency is an etiological factor for MS - No.
Mult Scler. 2019;25:639-641.
PubMed

WILLIAMS T, Chataway J
Immune-mediated encephalitis with daclizumab: The final nail.
Mult Scler. 2019;25:753-754.
PubMed Abstract available

THOUVENOT E, Hinsinger G, Demattei C, Uygunoglu U, et al
Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome.
Mult Scler. 2019;25:669-677.
PubMed Abstract available

March 2019

MEYER CE, Gao JL, Cheng JY, Oberoi MR, et al
Axonal damage in spinal cord is associated with gray matter atrophy in sensorimotor cortex in experimental autoimmune encephalomyelitis.
Mult Scler. 2019 Mar 7:1352458519830614. doi: 10.1177/1352458519830614.
PubMed Abstract available

BARANZINI SE
Insights into microbiome research 6: The role of consortia in studying the role of microbes in health and disease.
Mult Scler. 2019;25:336-337.
PubMed Abstract available

WATTJES MP, Killestein J
Imaging of meningeal inflammation should become part of the routine MRI protocol - No.
Mult Scler. 2019;25:331-333.
PubMed

ABSINTA M, Reich DS
Imaging of meningeal inflammation should become part of the routine MRI protocol - Yes.
Mult Scler. 2019;25:330-331.
PubMed

DEISENHAMMER F, Jank M, Lauren A, Sjodin A, et al
Prediction of natalizumab anti-drug antibodies persistency.
Mult Scler. 2019;25:392-398.
PubMed Abstract available

ROCCA MA, Riccitelli GC, Meani A, Pagani E, et al
Cognitive reserve, cognition, and regional brain damage in MS: A 2 -year longitudinal study.
Mult Scler. 2019;25:372-381.
PubMed Abstract available

AL-LOUZI O, Sotirchos ES, Vidal-Jordana A, Beh SC, et al
Characteristics of morphologic macular abnormalities in neuroimmunology practice.
Mult Scler. 2019;25:361-371.
PubMed Abstract available

February 2019

CUKER A, Bass AD, Nadj C, Agius MA, et al
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Mult Scler. 2019 Feb 20:1352458518816612. doi: 10.1177/1352458518816612.
PubMed Abstract available

BARANZINI SE
Insights into microbiome research 5: Mapping is first but function must come next.
Mult Scler. 2019;25:193-195.
PubMed Abstract available

HELLWIG K
We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - No.
Mult Scler. 2019;25:189-190.
PubMed

ALVAREZ E, Mowry EM
We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Yes.
Mult Scler. 2019;25:187-188.
PubMed

BOVE R
We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Commentary.
Mult Scler. 2019;25:190-192.
PubMed

HEDSTROM AK
Smoking and its interaction with genetics in MS etiology.
Mult Scler. 2019;25:180-186.
PubMed Abstract available

BSTEH G, Hegen H, Ladstatter F, Berek K, et al
Change of olfactory function as a marker of inflammatory activity and disability progression in MS.
Mult Scler. 2019;25:267-274.
PubMed Abstract available

BOVIS F, De Stefano N, Steinerman JR, Knappertz V, et al
Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS.
Mult Scler. 2019;25:217-223.
PubMed Abstract available

January 2019

BARANZINI SE
Insights into microbiome research 4: The computational analysis.
Mult Scler. 2019;25:21-22.
PubMed Abstract available

THOMPSON AJ, Antel J, Carroll WB, Geurts J, et al
MSJ 2019 - Editorial comment.
Mult Scler. 2019;25:4-5.
PubMed

PITT D, Ponath G
Astrocytes play a crucial role in the formation and evolution of MS lesions - Yes.
Mult Scler. 2019;25:15-17.
PubMed

KERLERO DE ROSBO N
Astrocytes play a crucial role in the formation and evolution of MS lesions - No.
Mult Scler. 2019;25:17-19.
PubMed

VIJAYASINGHAM L, Viswanathan S
A call for more research and global collaboration in South-East Asia to address challenges of DMT access and MS management in the region.
Mult Scler. 2019;25:130-131.
PubMed

PATEL VP, Feinstein A
The link between depression and performance on the Symbol Digit Modalities Test: Mechanisms and clinical significance.
Mult Scler. 2019;25:118-121.
PubMed Abstract available

MAZZOLA MA, Raheja R, Regev K, Beynon V, et al
Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells.
Mult Scler. 2019;25:63-71.
PubMed Abstract available

QUINTANA FJ
Astrocytes play a crucial role in the formation and evolution of MS lesions - Commentary.
Mult Scler. 2019;25:19-20.
PubMed

October 2018

PFEUFFER S
Sarcoidosis following alemtuzumab treatment: Autoimmunity mediated by T cells and interferon-gamma.
Mult Scler. 2018 Oct 11:1352458518804124. doi: 10.1177/1352458518804124.
PubMed

September 2018

BENJAMIN LA
A tale of two demyelinating diseases and Zika virus.
Mult Scler. 2018 Sep 18:1352458518799584. doi: 10.1177/1352458518799584.
PubMed

January 2018

BARONCINI D, Zaffaroni M, Moiola L, Lorefice L, et al
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study.
Mult Scler. 2018 Jan 1:1352458518754364. doi: 10.1177/1352458518754364.
PubMed Abstract available

April 2017

SIGNORI A, Izquierdo G, Lugaresi A, Hupperts R, et al
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.
Mult Scler. 2017 Apr 1:1352458517703800. doi: 10.1177/1352458517703800.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: